US Pat. No. 11,066,653

METHOD OF TRANSFORMING BACTERIAL CELLS

BASF SE, Ludwigshafen (D...


1. A method for producing a methylated DNA comprising the steps of(a) methylating in vitro or in vivo a DNA with a DNA methyltransferase comprising a methylation recognition sequence GCNGC to produce a methylated DNA containing 5-methylcytosine within the recognition sequence GCNGC, wherein the DNA methyltransferase comprises less than 35 amino acid residues between amino acid residue 72 and amino acid residue 106 according to the numbering of SEQ ID NO: 33; and
(b) isolating the methylated DNA.

US Pat. No. 11,066,654

METHODS AND COMPOSITIONS FOR REDUCING SERUM LIPIDS

ACCELERON PHARMA INC., C...


1. A method for reducing serum lipids in a subject having aberrant lipid levels, comprising administering to the subject an effective amount of a polypeptide selected from the group consisting of:a. a polypeptide comprising an amino acid sequence wherein the amino acid sequence consists of the amino acid sequence of SEQ ID NO: 8 or an amino acid sequence that differs from SEQ ID NO: 8 at no more than five amino acid positions;
b. a polypeptide produced by the expression in a mammalian cell of the nucleic acid of SEQ ID NO: 4; and
c. a polypeptide produced by the expression in a mammalian cell of the nucleic acid of SEQ ID NO: 6.

US Pat. No. 11,065,360

MEDICAL HYDROGEL COMPOSITION, AND MEDICAL HYDROGEL, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

Medprin Regenerative Medi...


1. A medical hydrogel kit, comprising:a first component comprising polylysine and polyethylene imine (PEI), wherein the polylysine is ?-polylysine having an average molecular weight of 3000 to 5000 Da or poly-L-lysine having an average molecular weight of 7500 to 300000 Da, the polylysine has a degree of polymerization of 20 or more, and the polylysine and the PEI have a mass ratio of 0.1 to 1;
a second component selected from the group consisting of 4-arm-polyethylene glycol-succinimidyl glutarate, 4-arm-polyethylene glycol-succinimidyl succinate, 4-arm-polyethylene glycol-succinimidyl carbonate, and combinations thereof, wherein the second component has an average molecular weight of 10,000 to 20,000 Da; and
a saline solution,
wherein the first component, the second component and the saline solution react to form a medical hydrogel having a degree of swelling of 5% to 47% when mixed together, and
wherein the formed medical hydrogel has a complete in vivo degradation time from 5 to 8 weeks.

US Pat. No. 11,066,398

SMALL MOLECULE C-MYC INHIBITORS

The Scripps Research Inst...


1. A method of treating c-Myc driven cancer, comprising administering an effective amount of 4-(2-(furan-2-yl)-6-(4-nitrophenyl)pyridin-4-yl)benzamide (CG-RS-44).
US Pat. No. 11,066,655

RNA POLYMERASE, METHODS OF PURIFICATION AND METHODS OF USE

President and Fellows of ...


1. A method of performing in vitro transcription comprising the steps of:providing a cDNA comprising a cyanophage Syn5 RNA polymerase (RNAP) promoter sequence and a nucleic acid template sequence, nucleotides and a Y564F mutant cyanophage Syn5 RNAP, wherein said Syn5 RNA Polymerase (RNAP) has at least 90% sequence identity to the amino acid sequence of SEQ ID NO:23; and
incubating the cDNA comprising the cyanophage Syn5 RNA polymerase (RNAP) promoter sequence and the nucleic acid template sequence, the nucleotides and the Y564F mutant cyanophage Syn5 RNAP together for a sufficient time to produce transcripts.

US Pat. No. 11,066,656

PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF

Halozyme, Inc., San Dieg...


1. A modified PH20 polypeptide, comprising one or more amino acid replacements in an unmodified PH20 polypeptide, wherein:the unmodified PH20 polypeptide consists of the amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 7 and 32-66;
the modified PH20 polypeptide exhibits increased hyaluronidase activity compared to the unmodified PH20 polypeptide not containing the amino acid replacement(s);
the amino acid replacement(s) confer(s) the increased hyaluronidase activity;
an amino acid replacement that confers the increased hyaluronidase activity is at a position corresponding to residue 309, with reference to amino acid positions of SEQ ID NO:3;
corresponding amino acid positions are identified by alignment of the PH20 polypeptide with the polypeptide having the sequence of amino acids of SEQ ID NO:3; and
the modified PH20 polypeptide has at least 91% sequence identity to the amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 7 and 32-66.

US Pat. No. 11,065,362

VISCOELASTIC HYDROGELS WITH FAST STRESS RELAXATION

President and Fellows of ...


1. A fast relaxing hydrogel comprising a plurality of alginate polymer chains and a plurality of linear spacer molecules, whereinthe plurality of alginate polymer chains have an average molecular weight of about 80 kDa or less;
the plurality of alginate polymer chains are ionically cross-linked to each other using Ca2+, wherein Ca2+ is present in said hydrogel at a concentration of about 2 mM to about 60 mM;
wherein each of the plurality of linear spacer molecules comprises a first end and a second end, wherein the first end is covalently attached to an alginate polymer chain and the second end is not attached to an alginate polymer chain, wherein each of the plurality of linear spacer molecules does not cross-link the alginate polymer chains, and wherein the plurality of linear spacer molecules physically separate the alginate polymer chains;
wherein the plurality of alginate polymer chains and the plurality of spacer molecules are present in the hydrogel at a ratio of at least 2:1 spacer molecule: alginate polymer chain;
wherein the length of each of the plurality of linear spacer molecules ranges from about 80 Angstroms to about 1500 Angstroms; and
wherein the hydrogel is characterized by a stress relaxation rate (?1/2) of 800 seconds or less.

US Pat. No. 11,066,657

METHODS AND COMPOSITIONS FOR STABILIZING TRANS-SPLICING INTEIN MODIFIED PROTEASES

AGRIVIDA, INC, Woburn, M...


1. A method of regulating protease activity comprising forming the home care product by adding an intein-modified protease that comprises a first precursor and a second precursor:the first precursor comprises an N-extein of a target protease fused to a solubility enhanced N-intein of a trans-splicing intein, and the carboxy terminus of the N-extein is fused to the amino terminus of the solubility enhanced N-intein,
the solubility enhanced N-intein comprises an N-intein and a first solubility enhancer, and the carboxy terminus of the N-intein is fused to the first solubility enhancer by a first linker;
the second precursor comprises a solubility enhanced C-intein of the trans-splicing intein fused to a C-extein of the target protease, and the carboxy terminus of the solubility enhanced C-intein is fused to the amino terminus of the C-extein,
the solubility enhanced C-intein comprises a C-intein and a second solubility enhancer, and the second solubility enhancer is fused to the amino terminus of the C-intein by a second linker;
each of the first solubility enhancer and the second solubility enhancer comprises the thioredoxin domain Trx, and the first precursor is separated from the second precursor prior to trans-splicing;
wherein the intein-modified protease has enhanced solubility and reduced activity compared to the target protease, and the activity of the target protease is at least partially restored upon trans-splicing of the intein-modified protease and fusion of the N-extein and the C-extein, and
wherein the first precursor consists of an amino acid sequence with at least 90% identity to SEQ ID NO: 1, and
the second precursor consists of an amino acid sequence with at least 90% identity to SEQ ID NO: 2.

US Pat. No. 11,065,364

COMBINATION WITH ALBUMIN, IN PARTICULAR FOR TREATING A CARTILAGE DEFECT

TETEC Tissue Engineering ...


1. A combination product comprising a first component and a second component, spatially separated from one another, wherein the first component comprises crosslinkable albumin and the second component comprises a polymer, wherein non-terminal monomer units of the polymer comprise at least partially an albumin-crosslinking group, wherein the polymer has a degree of substitution of 33 to 0.1 thiol groups per 100 monomer units, wherein the polymer is selected from the group consisting of hyaluronic acid functionalized by albumin-crosslinking groups and carboxymethylcellulose functionalized by albumin-crosslinking groups, wherein the albumin-crosslinking groups are thiol groups and the first component and the second component of the combination product are mixed to form a hydrogel.
US Pat. No. 11,066,658

LONG-ACTING COAGULATION FACTORS AND METHODS OF PRODUCING SAME

OPKO BIOLOGICS LTD., Kir...


1. A method of producing a CTP-modified coagulation Factor VII (FVII) polypeptide, comprising the step of attaching three to five chorionic gonadotrophin carboxy terminal peptides (CTPs) to the carboxy terminus of a coagulation FVII polypeptide, thereby producing a CTP-modified FVII polypeptide.
US Pat. No. 11,065,365

PREPARATION AND/OR FORMULATION OF PROTEINS CROSS-LINKED WITH POLYSACCHARIDES

ALLERGAN PHARMACEUTICALS ...


1. A kit comprising:(a) a prefilled syringe, wherein the prefilled syringe is filled with a tissue compatible composition comprising a protein selected from the group consisting of tropoelastin and albumin; a hyaluronic acid cross-linking molecule comprising one or more carboxyl groups; and at least one intermolecular cross-linkage comprising an amide bond between an amine of the protein and a carboxyl group of the hyaluronic acid cross-linking molecule; and
(b) instructions for use.

US Pat. No. 11,066,659

GLUCOSE ISOMERASE

NEW MATTERHORN, LLC, Wil...


1. A polypeptide comprising an amino acid sequence, wherein the amino acid sequence of the polypeptide is at least 95% identical to an amino acid sequence of SEQ ID NO: 1, wherein the amino acid sequence of the polypeptide comprises an amino acid substitution at one or more amino acid positions, wherein each of the one or more amino acid positions is independently selected from the group consisting of SEQ ID NO: 1 amino acid positions 10, 34, 35, 59, 89, and 90.
US Pat. No. 11,066,660

TECHNIQUE FOR AGGREGATING MACROMOLECULES TOGETHER WITH CELLS

PUBLIC UNIVERSITY CORPORA...


1. A method for preparing water-soluble polymer-loaded cells or cell aggregate, comprising:adding a cell suspension containing a water-soluble polymer and cells suspended therein to a medium containing a swellable material to aggregate the water-soluble polymer together with the cells by the swelling of the swellable material to form said water-soluble polymer-loaded cells or cell aggregate, wherein the concentration of the water-soluble polymer in the cell suspension is lower than the concentration of the swellable material in the medium.

US Pat. No. 11,065,368

DRUG ELUTING GRAFT CONSTRUCTS AND METHODS

Cook Biotech Incorporated...


1. An implantable device, comprising:a sheet graft material having a top side and a bottom side;
a plurality of drug depots attached to the sheet graft material;
wherein the sheet graft material has a porous matrix formed by a network of fibers, the porous matrix having pores formed between the fibers of the network;
wherein the drug depots each comprise solid deposits including a polymeric carrier and at least one drug, the solid deposits each including a first portion infiltrating pores of the porous matrix and a second portion external of the porous matrix;
wherein the sheet graft material has a thickness extending between the top surface and the bottom surface;
wherein the first portions of the drug depots extend only partially through the thickness of the sheet graft material;
wherein each said drug depot covers a corresponding depot-bearing portion of the sheet graft material;
wherein each said depot-bearing portion of the sheet graft material is thinner than depot-free portions of the sheet graft material occurring between the depot-bearing portions;
wherein each said depot-bearing portion of the sheet graft material is denser than the depot-free portions of the sheet graft material occurring between the depot-bearing portions;
wherein the drug depots include 5 or more drug depots each having a top surface with a surface area of about 50 mm2 to about 500 mm2;
wherein the first portions of the drug depots and the fibers form a hybrid matrix region including fibers entrained within the matrix of the first portions of the drug depots.

US Pat. No. 11,066,663

MULTIPLEXED DETERMINISTIC ASSEMBLY OF DNA LIBRARIES

Zymergen Inc., Emeryvill...


1. A method for generating libraries of polynucleotides, the method comprising:(a) combining a cloning vector, a first pool of polynucleotides and a second pool of polynucleotides, wherein the first pool contains pairs of polynucleotides, wherein each pair in the first pool contains a first polynucleotide and a second polynucleotide, wherein the second pool contains insert polynucleotides, wherein each insert polynucleotide in the second pool comprises a first assembly overlap sequence at its 5? end that is complementary to a 3? end of a first polynucleotide and a second assembly overlap sequence at its opposing 3? end that is complementary to a 5? end of a second polynucleotide in a pair of polynucleotides from the first pool, and wherein opposing ends of the cloning vector comprise sequence complementary to a 5? end of the first polynucleotide and a 3? end of the second polynucleotide for each pair in the first pool, wherein the first pool is generated by selecting pairs of polynucleotide sequences from a larger set of such sequences such that no polynucleotide from the first pool shares common sequence with any other polynucleotide from the first pool beyond a specified threshold, excluding designed assembly overlap sequences between the pairs of polynucleotides of the first pool and the insert polynucleotides of the second pool, or the pairs of polynucleotides of the first pool and the cloning vector; and
(b) assembling the cloning vector, the first pool and the second pool into a library of polynucleotides, wherein each polynucleotide in the library comprises an insert polynucleotide from the second pool and a pair of first polynucleotides and second polynucleotides from the first pool, wherein the assembling is performed via in vitro cloning methods or in vivo cloning methods.

US Pat. No. 11,066,664

INHIBITION OF MICRORNA-134 FOR THE TREATMENT OF SEIZURE-RELATED DISORDERS AND NEUROLOGIC INJURIES

ROYAL COLLEGE OF SURGEONS...


1. A method of treating a neurological condition that can precipitate seizure or epilepsy in an individual or animal, the method comprising administering an agent for inhibiting the activity of miR-134 to the individual or animal.
US Pat. No. 11,066,408

CRYSTALLINE BINARY SODIUM SALTS OF 5-METHYL-(6S)-TETRAHYDROFOLIC ACID WITH ORGANIC BASES

MERCK PATENT GMBH, Darms...


1. A crystalline salt of 5-methyl-(6S)-tetrahydrofolic acid, comprising(i) 5-methyl-(6S)-tetrahydrofolic acid,
(ii) sodium and
(iii) an organic base having a pKa value of 6 to 11;
wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to the sodium is 1:0.5 to 1:1.5 and the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to the organic base is 1:0.5 to 1:1.5;
or a hydrate or solvate thereof.

US Pat. No. 11,066,665

ANTITUMOR DRUG DELIVERY FORMULATION

PUBLIC UNIVERSITY CORPORA...


1. An antitumor drug delivery formulation for treating a subject having a tumor selected from the group consisting of glioma, pancreatic cancer, breast cancer, colorectal cancer, prostate cancer, liver cancer, lung cancer, leukemia, and lymphoma, the tumor having tumor cells expressing a higher level of TUG1 gene as compared to the corresponding normal tissues, or for preventing the subject from tumor metastasis, comprising a polymeric micelle comprising an antisense oligonucleotide that suppresses expression of the TUG1 gene as an active ingredient;wherein the polymeric micelle comprises a block copolymer having a cationic poly(amino acid) segment and a hydrophilic polymer chain segment and the antisense oligonucleotide, and
wherein the antisense oligonucleotide is bound to a cationic group of the cationic poly(amino acid) segment to form a complex and/or the antisense oligonucleotide is incorporated in the micelle; and the antisense oligonucleotide comprises RNA, DNA, or a combination thereof and targets a TUG1 nucleotide sequence selected from the group consisting of the nucleotide sequences of nucleotide numbers 3015 to 3035 and 3394 to 3412 in the nucleotide sequence of SEQ ID NO: 3.

US Pat. No. 11,066,666

BIOACTIVE RENAL CELLS

inRegen, Grand Cayman (K...


1. A method of providing a regenerative effect to a native kidney comprising in vivo contacting the native kidney with a composition comprising isolated human secreted vesicles produced by a renal cell population enriched for bioactive kidney cells,wherein the vesicles comprise exosomes or microvesicles comprising a paracrine factor that attenuates Plasminogen Activation Inhibitor-1 (PAI-1) and/or Transforming Growth Factor Beta (TGF?) signaling,
wherein the vesicles have been isolated from the renal cell population, and
wherein the regenerative effect comprises a reduction in renal fibrosis.

US Pat. No. 11,066,667

ORGANIC COMPOSITIONS TO TREAT APOC3-RELATED DISEASES

Arrowhead Pharmaceuticals...


1. A double-stranded RNAi agent for inhibiting expression of an APOC3 gene in a cell, comprising a first strand and a second strand, wherein said first strand is less than 30 nucleotides in length and comprises SEQ ID NO: 132, wherein the second strand is substantially complementary to the first strand, and wherein the 3? end of the first strand terminates in a phosphate or modified internucleoside linker and further comprises, in 5? to 3? order: a spacer, a second phosphate or modified internucleoside linker, and a 3? end cap.
US Pat. No. 11,066,668

COMPOSITIONS AND METHODS FOR MODULATION OF IKBKAP SPLICING

Ionis Pharmaceuticals, In...


1. A single-stranded modified oligonucleotide consisting of 15 to 22 linked nucleosides having a nucleobase sequence comprising at least 15 contiguous nucleobases of a nucleobase sequence selected from SEQ ID NO: 15 and SEQ ID NO: 16;wherein the modified oligonucleotide comprises at least one modified internucleoside linkage and each nucleoside comprises a modified sugar moiety.

US Pat. No. 11,066,669

OLIGONUCLEOTIDES FOR MODULATING ATXN2 EXPRESSION

Hoffmann-La Roche Inc., ...


1. An antisense oligonucleotide having the sequence:ATTTtactttaaccTCC (SEQ ID NO: 7)
wherein capital letters are beta-D-oxy LNA nucleosides, lowercase letters are DNA nucleosides, all LNA C are 5-methyl cytosine, all internucleoside linkages are phosphorothioate internucleoside linkages.

US Pat. No. 11,066,670

INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN, ACID LABILE SUBUNIT (IGFALS) AND INSULIN-LIKE GROWTH FACTOR 1 (IGF-1) IRNA COMPOSITIONS AND METHODS OF USE THEREOF

Alnylam Pharmaceuticals, ...


1. A double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of an insulin-like growth factor binding protein, acid labile subunit (IGFALS) gene, wherein the dsRNA agent comprises a sense strand and an antisense strand forming a double stranded region, wherein said sense strand comprises the nucleotide sequence 5?-UUCUGGCUGGACGUCUCGCAA-3? (SEQ ID NO:74) and the antisense strand comprises the nucleotide sequence 5?-UUGCGAGACGUCCAGCCAGAAGG-3? (SEQ ID NO:131); and wherein the dsRNA agent comprises at least one modified nucleotide.
US Pat. No. 11,066,671

USE OF THERAPEUTIC AGENTS

The Walter and Eliza Hall...


1. A method of reducing ocular neovascularization in a subject wherein the ocular neovascularization is pathological choroidal neovascularization or retinal neovascularization, the method comprising treating the subject with a VEGF antagonist, determining that the subject is unresponsive to the VEGF antagonist treatment, and administering to the subject an agent, wherein the agent is a small molecule inhibitor that binds to Mcl-1 polypeptide and suppresses Mcl-1 polypeptide activity, wherein the agent is highly specific for Mcl-1 verses non-Mcl-1 Bcl-2 polypeptides, wherein the agent is active in endothelial cells and suppresses Mcl-1 activity in endothelial cells and reduces the number of angiogenic vascular endothelial cells while substantially sparing quiescent vascular endothelial cells in the eye, wherein the agent is in a pharmaceutical or physiological composition and the pharmaceutical or physiological composition is administered topically to the eye region or ocularly, and wherein administering the agent is for a time and under conditions effective to reduce the formation of new blood vessels in the eye of the subject.
US Pat. No. 11,065,378

METHOD FOR EXTRACORPOREAL REMOVAL OF A PATHOGENIC MICROBE, AN INFLAMMATORY CELL OR AN INFLAMMATORY PROTEIN FROM BLOOD

ExThera Medical Corporati...


1. A method for extracorporeal removal of an inflammatory cell from mammalian blood, comprising the steps:a) providing a sample of mammalian blood,
b) bringing said sample into contact with a carbohydrate immobilized on a solid substrate, said carbohydrate having a binding affinity for an inflammatory cell, under conditions allowing binding of any inflammatory cells in said blood sample to the carbohydrate, wherein said immobilized carbohydrate is immobilized heparin having a terminal residue, wherein heparin immobilization consists of a single covalent link of said terminal residue to said solid substrate by covalent end-point attachment,
c) separating the sample from the solid substrate, such that said inflammatory cell is at least partially retained on the solid substrate, and
d) recovering said sample containing a reduced amount of said inflammatory cell.

US Pat. No. 11,066,672

METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF TRANSTHYRETIN (TTR) BY DOUBLE STRANDED RNA

Dicerna Pharmaceuticals, ...


1. A double stranded nucleic acid (dsNA) comprising first and second oligonucleotide strands, wherein the first strand is 15-66 nucleotides in length and the second strand is 20-66 nucleotides in length, wherein the second oligonucleotide strand has a region of complementary to a target transthyretin mRNA sequence selected from SEQ ID NOs: 2052, 2054, 2060, 2062, 2064, 2066, 2068, 2084, 2085, and 2087 and is capable of reducing expression of transthyretin mRNA containing the target mRNA sequence when the dsNA is introduced into a mammalian cell, wherein the second oligonucleotide strand comprises a sequence selected from the group consisting of SEQ ID NOs: 516, 518, 524, 526, 528, 530, 532, 548, 549 and 551, and wherein the dsNA comprises RNA and has at least one modified nucleotide.
US Pat. No. 11,066,673

POLYCOMB-ASSOCIATED NON-CODING RNAS

The General Hospital Corp...


1. A method of inducing expression of a non-imprinted target gene in a cell, wherein expression of the target gene is inhibited by a PRC2-binding RNA, and wherein recruitment of PRC2 to the target gene by the PRC2-binding RNA results in an increase in trimethylation of histone H3-lysine27 at the target gene, the method comprising delivering to the cell a composition comprising an isolated oligonucleotide mimetic that specifically interferes with binding of PRC2 to a PRC2-binding region of the PRC2-binding RNA without inducing degradation of the PRC2-binding RNA by RNAse H, wherein the PRC2-binding region has a nucleotide sequence protected from nucleases during an RNA immunoprecipitation procedure using an antibody directed against PRC2, wherein the PRC2-binding RNA is not ANRIL lncRNA and is transcribed from a sequence of the chromosomal locus of the target gene, and wherein a decrease in recruitment of PRC2 to the target gene in the cell and a decrease in trimethylation of histone H3-lysine27 at the target gene following delivery of the oligonucleotide mimetic to the cell, compared with an appropriate control cell to which the oligonucleotide mimetic has not been delivered, indicates effectiveness of the oligonucleotide mimetic.
US Pat. No. 11,066,674

CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN

The United States of Amer...


1. A chimeric antigen receptor (CAR) comprising a means for binding to B-cell Maturation Antigen (BCMA); a CD28 transmembrane domain or a CD8? transmembrane domain; a 4-1BB intracellular T cell signaling domain; and a CD3? intracellular T cell signaling domain; wherein the means for binding to BCMA comprises (a) an antigen-binding portion of a monoclonal antibody that binds BCMA or (b) a variable region of a monoclonal antibody that binds BCMA,wherein the means for binding to BCMA comprises the (i) heavy chain complementarity determining region (CDR)1, (ii) heavy chain CDR2, (iii) heavy chain CDR3, (iv) light chain CDR1, (v) light chain CDR2, and (vi) light chain CDR3 of one amino acid sequence selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12.

US Pat. No. 11,065,123

COMPRESSION RESISTANT IMPLANTS INCLUDING AN OXYSTEROL AND METHODS OF USE

Warsaw Orthopedic, Inc., ...


1. A compression resistant implant configured to fit at or near a bone defect to promote bone growth, the compression resistant implant comprises porous ceramic particles in an amount of about 50 wt % to about 80 wt %; a biodegradable polymer comprising collagen in an amount of about 8.0 wt % to about 13 wt % based on a total weight of the implant; (3S,5S,6S,8R,9S,10R,13S,14S,17S) 17-((S)-2-hydroxyoctan-2-yl)-10, 13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthrene-3,6-diol (Oxy133) in an amount of about 5.0 wt % to about 45 wt % of the implant; and carboxymethylcellulose in an amount of from about 2 wt % to about 4 wt %, wherein the Oxy133 is in anhydrous form.
US Pat. No. 11,066,675

INCREASED NUCLEIC-ACID GUIDED CELL EDITING IN YEAST

Inscripta, Inc., Boulder...


1. A method for performing editing in yeast comprising:providing a population of yeast cells;
transforming the population of yeast cells with a population of editing vectors, wherein each editing vector comprises: a yeast 2? backbone; a 2? origin of replication; a first non-minimal or non-core constitutive promoter driving transcription of a gRNA sequence and donor DNA sequence with followed by a terminator element 3? to the gRNA and donor DNA sequences; a second non-minimal or non-core constitutive promoter driving transcription of a coding sequence for a degron-survival marker fusion gene followed by a terminator element 3? to the degron-survival marker fusion gene; a third non-minimal or non-core constitutive promoter driving transcription of a nuclease coding sequence with a terminator element 5? to the nuclease coding sequence; and an origin of replication for propagation of the editing vector in bacteria;
growing the transformed yeast cells in selective medium to select for cells expressing a degron-survival marker fusion protein;
providing conditions to allow the transformed yeast cells to edit nucleic acid sequences in the yeast cells; and
growing the edited yeast cells.

US Pat. No. 11,066,677

PLANTS WITH ENHANCED TOLERANCE TO MULTIPLE ABIOTIC STRESSES

Kansas State University R...


1. A method of producing a genetically-modified plant having enhanced tolerance to heat stress as compared to a control plant, said method comprising:transforming a plant with a heterologous, abiotic stress tolerance gene to yield a genetically-modified plant having ectopic expression of said heterologous, abiotic stress tolerance gene, wherein said stress tolerance gene is Arabidopsis monothiol glutaredoxin AtGRXS17, wherein said gene encodes glutaredoxin GRXS17, thereby enhancing the tolerance of said genetically-modified plant to heat stress, and
wherein said genetically-modified plant is selected from the group consisting of wheat, oat, barley, rice, maize, millet, rye, sorghum, triticale, buckwheat, quinoa, soybeans, beans, peas, alfalfa, potatoes, sweet potatoes, cassava, yam, tomatoes, peppers, tobacco, and cotton.

US Pat. No. 11,066,678

METHODS OF IMPROVING TITER IN TRANSFECTION-BASED PRODUCTION SYSTEMS USING EUKARYOTIC CELLS


1. A high titer transfection-based lentiviral vector production method, comprising:seeding mammalian cells at a cell density of at least 5×104 cells/cm2 4 to 5 days prior to cell harvest and transfection;
harvesting a confluent population of the seeded cells that have progressed beyond log phase of growth at least 24 hours prior to transfection;
transfecting the cells by mixing the harvested population with transfection reagents and plasmid DNA comprising a lentiviral vector expression plasmid;
re-seeding the transfected cells into a culture vessel at a transfection cell density of at least 1.25×105 cells per square centimeter;
capturing the lentiviral vectors from the cell-free supernatant of the transfected, re-seeded cells using an anion-exchange capsule; and
concentrating the captured lentiviral vectors using a Polysulfone (PS) or Polyether (PES) tangential-flow filtration (TFF) module, wherein the concentrating step comprises (a) applying a trans-membrane pressure of 5-6 psi, (b) applying a shear of 5000 to 6000 s?1 to the TFF module, and (c) introducing air into the TFF module before collecting concentrated viral vectors.

US Pat. No. 11,066,679

CLOSED-ENDED LINEAR DUPLEX DNA FOR NON-VIRAL GENE TRANSFER

University of Massachuset...


1. An isolated nucleic acid comprising a nucleic acid insert comprising a transgene;wherein the insert is flanked by at least two adeno-associated virus (AAV) inverted terminal repeat (ITR) sequences;wherein the at least two ITR sequences are asymmetric and covalently linked with respect to one another;
wherein each of the at least two ITR sequences has an operative terminal resolution site and a rolling circle replication protein rep binding element (RBE);wherein a first ITR sequence is interrupted by a cross-arm sequence forming two opposing, lengthwise-symmetric stem-loops, each of the opposing lengthwise-symmetric stem-loops having a stem portion in the range of 5 to 15 base pairs in length and a loop portion having 2 to 5 unpaired deoxyribonucleotides;
wherein a second ITR sequence is interrupted by a truncated cross-arm sequence having one or more deletions of between 11 and 20 nucleotides in a palindromic sequence region B-B? and/or a palindromic sequence region C-C?; and



wherein the isolated nucleic acid is a closed-ended linear duplex DNA (ceDNA).
US Pat. No. 11,066,680

IL6R BLOCK CAR-T TRANSGENIC VECTOR FOR ALLEVIATING CRS, PREPARATION METHOD THEREOF

SHANGHAI UNICAR-THERAPY B...


1. A CAR-T transgenic vector for alleviating cytokine release syndrome (CRS) by blocking IL6R, said vector comprising:an AmpR sequence comprising ampicillin resistance gene having the sequence of SEQ ID NO. 1 for amplifying target bacterial strains;
a prokaryotic replicon pUC Ori sequence having the sequence of SEQ ID NO: 2 for plasmid replication;
a SV 40 Ori sequence of viral replicator having the sequence of SEQ ID NO: 3 for enhancing replication in eukaryotic cells;
an eWPRE enhanced posttranscriptional regulatory element of groundhog hepatitis B virus having the sequence of SEQ ID NO: 11 for enhancing the expression efficiency of transgene;
a human EF1? promoter having the sequence of SEQ ID NO. 12 for eukaryotic transcription of chimeric antigen receptor genes;
a lentivirus packaging cis-element for lentivirus packaging;
a nucleotide sequence encoding a humanized single chain antibody fragment of human IL6R, wherein the humanized single chain antibody fragment of the human IL6R is selected from the group consisting of (i) IL6RscFv1 encoded by the sequence of SEQ ID NO: 21, (ii) IL6RscFv2 encoded by the sequence of SEQ ID NO: 22 and (iii) IL6RscFv3 encoded by the sequence of SEQ ID NO: 23;
an IRES ribosome binding sequence having the sequence of SEQ ID NO. 25 for co-transcription and expression of proteins;
a nucleotide sequence having the sequence of SEQ ID NO 26 encoding IL-6 signal peptide;
a nucleotide sequence having the sequence of SEQ ID NO: 27 encoding human antibody FC segment; and
a nucleotide sequence encoding a second-generation chimeric antigen receptor (CAR) or a third generation CAR.

US Pat. No. 11,066,681

PRODUCTION OF ITACONIC ACID

LESAFFRE ET COMPAGNIE, P...


1. A method to increase production of itaconic acid in a micro-organism, comprising:(i) culturing a micro-organism selected from the group of strains as deposited under no. CBS 141661 and CBS 141662 with the Westerdijk Fungal Biodiversity Institute in a suitable medium;
(ii) inhibiting expression or function of itaconyl-CoA transferase (EC 2.8.3.-), itaconyl-CoA hydratase (citramalyl-CoA hydro-lyase; EC 4.2.1.56), citramalyl CoA lyase (EC 4.1.3.25), or a combination thereof in the micro-organism;and providing the micro-organism with a gene encoding for the enzyme 2-methylcitrate dehydratase, wherein the production of itaconic acid is increased at least 2 fold compared to a parental micro-organism.


US Pat. No. 11,066,682

METHODS AND COMPOSITIONS FOR IMPROVED PRODUCTION OF FATTY ACIDS AND DERIVATIVES THEREOF

Genomatica, Inc., San Di...


1. A method of producing a fatty acid, fatty acid ester, fatty aldehyde or a fatty alcohol, the method comprising:(a) providing a host cell which is genetically engineered to have an increased level of expression of FadR polypeptide comprising the amino acid sequence of SEQ ID NO:1, optionally comprising a mutation at the amino acid residue serine 219 of SEQ ID NO:1 which is substituted by asparagine, compared to corresponding wild-type host cell, wherein the engineered host cell is a bacterial cell,
(b) culturing the engineered host cell in a culture medium comprising a carbohydrate carbon source under conditions permissive for the production of the fatty acid, fatty acid ester, fatty aldehyde or the fatty alcohol, and
(c) isolating the fatty acid, fatty acid ester, fatty aldehyde or the fatty alcohol, from the engineered host cell, wherein the engineered host cell produces 15% or more total fatty acid species compared to corresponding wild-type host cell under the same cultivation condition, wherein the fatty acid species are the fatty acid, fatty acid ester, fatty aldehyde and/or fatty alcohol.

US Pat. No. 11,066,683

RECOMBINANT CORYNEBACTERIUM CAPABLE OF PRODUCING BILIVERDIN IX-ALPHA AND METHOD OF PRODUCING BILIVERDIN IX-ALPHA USING THE SAME

Korea University Research...


1. A recombinant strain of a genus Corynebacterium having capability to produce biliverdin IX-alpha, wherein a hemA gene comprising the nucleotide sequence of SEQ ID NO:1 and a hemL gene comprising the nucleotide sequence of SEQ ID NO:2 are amplified, and wherein a hemQ gene comprising the nucleotide sequence of SEQ ID NO:3 or a hmuO gene comprising the nucleotide sequence of SEQ ID NO:4 is introduced by a recombinant vector in a form of hemQ or hmuO.
US Pat. No. 11,066,684

PRODUCTION OF BIOACTIVE OLIGOSACCHARIDES

The Regents of the Univer...


1. A method of generating oligosaccharides from polysaccharides, the method comprising,reacting polysaccharides in a reaction mixture under suitable reaction conditions with hydrogen peroxide and a transition metal or an alkaline earth metal; followed by
quenching the reaction by adding a base and/or cleaving glycosidic linkages in the polysaccharides by adding a base, thereby generating a mixture of oligosaccharides from the polysaccharides.

US Pat. No. 11,066,685

FERMENTATION PROCESS FOR PRODUCING MONOSACCHARIDES IN FREE FORM FROM NUCLEOTIDE-ACTIVATED SUGARS

Jennewein Biotechnologie ...


1. A process for producing L-fucose in free form using a recombinant host microorganism, the process comprising:A) obtaining a microorganism comprising GDP-L-fucose, wherein the microorganism comprises a recombinant nucleic acid sequence encoding a 1,2-fucosyltransferase that catalyzes the hydrolysis of the GDP-L-fucose to release the L-fucose from the GDP-L-fucose to produce free L-fucose in the absence of an acceptor molecule, wherein the 1,2-fucosyltransferase is an alpha-1,2-fucosyltransferase encoded by a wbgL gene from Escherichia coli set forth in SEQ ID NO: 3 or a 1,2-fucosyltransferase encoded by a futC gene from Helicobacter pylori set forth in SEQ ID NO: 4, or a gene encoding a 1,2-fucosyltransferase having at least 90% amino acid identity to the 1,2-fucosyltransferase encoded by the wbgL gene set forth in SEQ ID NO: 3 or the futC gene set forth in SEQ ID NO: 4;
B) cultivating the recombinant microorganism in a medium suitable for growing the microorganism, and
C) recovering the free L-fucose from the medium, wherein the microorganism is unable to metabolize the free L-fucose, and wherein the microorganism is Escherichia coli or a Saccharomyces spp.

US Pat. No. 11,066,429

PROCESS FOR PRODUCING ACETOXY-BEARING SILOXANES

Evonik Operations GmbH, ...


1. A process for producing acidic, a superacidic, or a trifluoromethanesulfonic acid-acidified, end-equilibrated, acetoxy-bearing siloxane, wherein the process comprisesreacting cyclic siloxanes comprising D4 and/or D5,
and/or mixtures of cyclic branched siloxanes of the D/T type,
optionally in admixture with hydroxyl-bearing siloxanes and/or acetoxy- and/or alkoxy-bearing silanes and/or siloxanes,
with acetic anhydride using the acid, superacid, or trifluoromethanesulfonic acid, as catalyst and with addition of acetic acid,
wherein the cyclic branched siloxanes of the D/T type are mixtures of cyclic branched siloxanes of the D/T type, which contain not only siloxanes comprising D and T units but optionally also siloxanes comprising Q units with the proviso that in these mixtures the proportion of Si atoms derived from Q units is ?10% by mass to ?0% by mass, based on the entirety of all Si atoms, wherein if no mixtures of cyclic branched siloxanes of the D/T type which contain siloxanes comprising Q units are employed.

US Pat. No. 11,066,686

RNA POLYMERASE VARIANTS

ModernaTX, Inc., Cambrid...


1. A method of performing an in vitro transcription (IVT) reaction, comprising combining a deoxyribonucleic acid (DNA) with a T7 ribonucleic acid (RNA) polymerase, nucleoside triphosphates and buffer, wherein the T7 RNA polymerase variant comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 1 modified to comprise an amino acid substitution at position 47, and the T7 RNA polymerase variant has RNA polymerase activity.
US Pat. No. 11,066,687

5?-INOSINIC ACID DEHYDROGENASE AND METHOD OF PREPARING 5?-INOSINIC ACID USING THE SAME

CJ CHEILJEDANG CORPORATIO...


1. A variant of 5?-inosinic acid dehydrogenase comprising the amino acid sequence of SEQ ID NO:2 and having i) substitution of the amino acid at position 377 with threonine, ii) substitution of the amino acid at position 499 with isoleucine, or iii) substitution of the amino acid at position 377 with threonine and substitution of the amino acid at position 499 with isoleucine.
US Pat. No. 11,069,518

MULTILAYER INSULATION FOR MASS SPECTROMETRY APPLICATIONS

Thermo Finnigan LLC, San...


8. A mass spectrometer comprising:a vacuum manifold having an interior space;
a vacuum pump configured to maintain the interior space at a pressure below 5×10-5 torr;
a heated component located within the interior space; and
a multilayer insulator located within the interior space, the multilayer insulator comprising:an inner layer with a first surface oriented towards the ion source and a second surface oriented away from the heated component;
an outer layer with a third surface oriented towards the heated component and a fourth surface oriented towards an interior surface of the vacuum manifold or other heat sink, the inner layer and the outer layer displaced apart from one another, and
one or more spacers separating the inner layer and the outer layer.


US Pat. No. 11,066,431

COMPLEX AND METHOD FOR PRODUCING SAME

KYOTO UNIVERSITY, Kyoto ...


1. An isolated complex represented by formula (1A):SnXn.(m)L??(1A)
wherein X is an iodine atom or bromine atom, L is N,N-dimethylformamide, n is a value from 1.5 to 2.5, and m is a value from 0.3 to 1.9.

US Pat. No. 11,066,688

METHOD FOR PREPARING A STEVIOL GLYCOSIDE COMPOSITION

DSM IP ASSETS B.V., Heer...


1. A method for preparing a steviol glycoside composition, which method comprises:providing a fermentation broth comprising a steviol glycoside;
subjecting the fermentation broth to a solid-liquid separation and a crystallization, to yield a first steviol glycoside composition;
combining the first steviol glycoside composition with water to form a steviol glycoside solution; and
recrystallizing, at pH 7.0 or above, a second steviol glycoside composition from the steviol glycoside solution, wherein:the resulting second steviol glycoside composition comprises less nitrogen than the first steviol glycoside composition;
the nitrogen in the resulting second steviol glycoside composition is no more than 800 ppm; and
the resulting second steviol glycoside composition comprises at least 80% on a dry weight basis of at least one steviol glycoside selected from the group consisting of rebaudioside A, rebaudioside D, and rebaudioside M.


US Pat. No. 11,066,432

ETHER PHOSPHOLIPIDS AND METHOD FOR PRODUCING THE SAME

Institute of Rheological ...


1. A method for producing ether phospholipids derived from bivalve tissues comprising:(A) a step of processing total lipids of bivalve tissues with water-soluble ketone solvent to get bivalve phospholipids without neutral fat;
(B) a step of providing extraction processing from the bivalve phospholipids without neutral fat obtained by the step (A) with ether or petroleum ether to get a glycerophospholipid; and
(C) a step of reacting the glycerophospholipids obtained by the step (B) with phospholipase A1 to decompose mixed diacyl-glycerophospholipids, followed by solution partitioning to get a purified ether phospholipid.

US Pat. No. 11,065,656

METHOD AND APPARATUS FOR PRODUCING A PRODUCT

SHINKO TECNOS CO., LTD., ...


1. A method for producing a product by hydrolyzing a raw material containing vegetable waste comprising,a hydrolysis treatment step of subjecting the raw material to a hydrolysis treatment with steam,
a washing step of washing the hydrolyzed raw material with a washing liquid, and
a solid-liquid separation step of separating the washed raw material into a solid component and a liquid component,
wherein at least one of the solid component or the liquid component is used as the product,
the solid component separated from the raw material contains potassium at a concentration of 0.2% DM or less, and
biomass fuel is produced from the solid component.

US Pat. No. 11,065,914

RUBBER-COVERED TEXTILE CORDS, TIRES CONTAINING SAME, AND RELATED METHODS

Bridgestone Americas Tire...


1. Textile cords covered with a rubber composition, the rubber composition comprising:a. at least one conjugated diene monomer-containing polymer or copolymer;
b. silica filler in an amount of up to 20 phr;
c. silane coupling agent in an amount of up to 2 phr and wherein the amount of silane coupling agent comprises no more than 10% by weight of the amount of silica filler;
d. carbon black filler in an amount of up to 40 phr; and
e. a cure package,
wherein the total amount of silica filler and carbon black is no more than 50 phr, and wherein the rubber composition contains less than 0.5 phr of cobalt-containing compounds.

US Pat. No. 11,066,690

FLAVIN-BINDING GLUCOSE DEHYDROGENASE VARIANT

KIKKOMAN CORPORATION, No...


1. An electrode comprising a modified glucose dehydrogenase using a flavin adenine dinucleotide (FAD) as a coenzyme (FAD-GDH), wherein the modified FAD-GDH is based on a FAD-GDH before amino acid substitution selected from the group consisting of (i) to (iv):(i) FAD-GDH comprising an amino acid sequence having an identity of 85% or more with the amino acid sequence of SEQ ID NO: 1 and having glucose dehydrogenase activity;
(ii) FAD-GDH comprising an amino acid sequence having an identity of 85% or more with the amino acid sequence of SEQ ID NO: 1 over the full length and having an identity of 90% or higher identity between the homologous region consisting of positions 31 to 41, 58 to 62, 71 to 85, 106 to 116, 119 to 127, 132 to 134, 136 to 144, 150 to 153, 167 to 171, 219 to 225, 253 to 262, 277 to 281, 301 to 303, 305 to 312, 314 to 319, 324 to 326, 332 to 337, 339 to 346, 348 to 354, 386 to 394, 415 to 417, 454 to 459, 476 to 484, 486 to 491, 508 to 511, 518 to 520, 522 to 524, 526 to 528, 564 to 579, 584 to 586, 592 to 595, 597 to 599, 607 to 617 and 625 to 630 of SEQ ID NO: 1 and the homologous region of the FAD-GDH consisting of corresponding positions and having glucose dehydrogenase activity;
(iii) FAD-GDH comprising an amino acid sequence having an identity of 85% or more with the amino acid sequence of SEQ ID NO: 1 over the full length and having an identity of 95% or higher identity between the homologous region consisting of positions 31 to 41, 58 to 62, 71 to 85, 106 to 116, 119 to 127, 132 to 134, 136 to 144, 150 to 153, 167 to 171, 219 to 225, 253 to 262, 277 to 281, 301 to 303, 305 to 312, 314 to 319, 324 to 326, 332 to 337, 339 to 346, 348 to 354, 386 to 394, 415 to 417, 454 to 459, 476 to 484, 486 to 491, 508 to 511, 518 to 520, 522 to 524, 526 to 528, 564 to 579, 584 to 586, 592 to 595, 597 to 599, 607 to 617 and 625 to 630 of SEQ ID NO: 1 and the homologous region of the FAD-GDH consisting of corresponding positions and having glucose dehydrogenase activity; and
(iv) FAD-GDH comprising an amino acid sequence having an identity of 90% or more with the amino acid sequence of SEQ ID NO: 1 over the full length and having glucose dehydrogenase activity;

and wherein the modified FAD-GDH comprises an amino acid substitution at the position(s) corresponding to the following amino acid(s):the amino acid at the 175th position in the amino acid sequence of SEQ ID NO: 1 is cysteine, and
the amino acid at the 214th position in the amino acid sequence of SEQ ID NO: 1 is cysteine; and
has an improved thermal stability compared to the FAD-GDH before the amino acid substitution.

US Pat. No. 11,065,657

COMPOSITIONS AND METHODS FOR OXIDIZING AND SEQUESTERING CARBON AND STABILIZING METALS


1. A method of oxidizing an organic compound in a substrate, the method comprising treating the substrate at a hydroxide concentration of about 1×10?4 M or greater with:an oxidant capable of producing free radicals in an amount sufficient to oxidize carbon in the substrate; and
a first metal, wherein the first metal is a metal wherein a carbonate thereof has a lower solubility product constant than a hydroxide thereof, wherein the first metal is added to the substrate in an amount sufficient to precipitate carbonate from the substrate, wherein the substrate is treated with an amount of the first metal sufficient to maintain a concentration of an ionic form of the first metal in the substrate equal to or greater than a concentration of total carbonate and bicarbonate ion in the substrate.

US Pat. No. 11,066,435

GREEN METHODS FOR PREPARING HIGHLY CO2 SELECTIVE AND H2S TOLERANT METAL ORGANIC FRAMEWORKS

KING ABDULLAH UNIVERSITY ...


1. A method of preparing a metal-organic framework, comprising:grinding a metal node precursor with a ligand precursor to form a mixture of precursors, wherein the ligand precursor includes one or more of pyrazine, pyrimidine, pyridazine, triazine, thiazole, oxazole, pyrrole, imidazole, pyrazole, oxadiazole, thiadiazole, quinoline, benzoxazole, benzimidazole, 1,4-Diazabicyclo[2.2.2]octane, 1,2-bis(4-pyridyl)acetylene, and tautomers thereof;
wetting the mixture of precursors with one or more drops of water; and
heating the wetted mixture to an activation temperature to obtain a metal-organic framework.

US Pat. No. 11,066,692

REAL-TIME MONITORING

Promega Corporation, Mad...


1. A method comprising:(a) providing extracellularly to a cell:(i) a luciferase enzyme, wherein the luciferase enzyme generates a detectable luminescent signal upon interaction with a substrate selected from furimazine, coelenterazine, or luciferin, and wherein the luciferase enzyme is incapable of entering the cell; and
(ii) a pro-substrate comprising a substrate moiety and a blocking moiety that is capable of entering the cell, wherein the pro-substrate is selected from pro-furimazine, pro-coelenterazine, and pro-luciferin substrate, wherein interaction of the pro-substrate with an intracellular enzyme that cleaves the blocking moiety from the substrate moiety thereby converting the pro-substrate into the substrate for the luciferase enzyme, wherein the substrate is capable of exiting the cell; and

(b) detecting the detectable luminescent signal generated by the interaction of the substrate and the luciferase enzyme, wherein real-time magnitude of the luminescent detectable signal correlates with the real-time intracellular amount of the intracellular enzyme.

US Pat. No. 11,067,720

MEDICAL DEVICES HAVING HOMOGENEOUS CHARGE DENSITY AND METHODS FOR MAKING SAME


1. A silicone hydrogel contact lens comprising between about 50 ppm and about 1 wt % of at least one uncrosslinked statistical copolymer comprising about 80 to about 20 mol % units from at least one non-ionic hydrophilic monomer and at least 20 mol % of at least one anionic repeating unit from an anionic monomer distributed randomly throughout said polymer, wherein said anionic monomer and said non-ionic hydrophilic monomer have the same reactive functionality.
US Pat. No. 11,066,693

METHODS FOR DIAGNOSING LHRH OR HCG/LH RECEPTOR EXPRESSING TUMORS, CANCERS AND NEOPLASIAS

ESPERANCE PHARMACEUTICALS...


1. A method of analyzing a pancreatic, hepatic, melanoma, kidney, gastrointestinal, lung, lymphoma or leukemia sample, the method comprising:(a) contacting the pancreatic, hepatic, melanoma, kidney, gastrointestinal, lung, lymphoma or leukemia sample from a subject, with a hormone polypeptide or hormone polypeptide analog that binds to LHRH- or hCG/LH receptors under conditions allowing the hormone or hormone analog to bind the LHRH- or hCG/LH receptors;
(b) determining an amount of LHRH- or hCG/LH receptors in the sample by detecting the amount of hormone polypeptide or hormone polypeptide analog that is bound to the LHRH- or hCG/LH receptors in the sample;
(c) contacting cells obtained from the sample with a peptide comprising the cytotoxic sequence KFAKFAKKFAKFAKKFAKQHWSYGLRPG (SEQ ID NO: 1); and
(d) after the contacting of (c), determining the IC50 value according to a sensitivity of the cells to SEQ ID NO:1, wherein the IC50 value is 5.5 ?M or less and wherein greater LHRH- or hCG/LH receptor expression indicates increased sensitivity of the cells.

US Pat. No. 11,066,694

AFFINITY TAG NUCLEIC ACID AND PROTEIN COMPOSITIONS, AND PROCESSES FOR USING SAME

Enzo Biochem, Inc., New ...


1. A composition of matter, comprising:a chimeric molecule comprisinga polynucleic acid portion comprising one or more energy transfer donors or energy transfer acceptors, and
a peptide affinity tag portion covalently attached to the polynucleic acid portion;

a first polynucleic acid molecule hybridized to the polynucleic acid portion of the chimeric molecule; and
a second polynucleic acid molecule hybridized to the first polynucleic molecule and not to the polynucleic acid portion of the chimeric molecule, said second polynucleic acid comprising one or more energy transfer donors or energy transfer acceptors,

wherein when the polynucleic acid portion comprises one or more energy transfer donors, the second polynucleic acid molecule comprises one or more energy transfer acceptors and when the polynucleic acid portion comprises one or more energy transfer acceptors, the second polynucleic acid molecule comprises one or more energy transfer donors.
US Pat. No. 11,066,438

SQUALAMINE SOLID FORMS AND METHODS OF MAKING THE SAME

Enterin, Inc., Philadelp...


1. An isolated squalamine phosphate solid form designated as Form 2, which is at least 95% purified and having the following:(a) an X-ray powder diffraction pattern comprising a peak, in terms of 2-theta, at about 15.2° and at about 22.9°;
(b) an X-ray powder diffraction pattern as shown in FIG. 15 with ±0.2°;
(c) a differential scanning calorimetry (DSC) thermogram comprising an endothermic peak at about 90.9° C.;
(d) a differential scanning calorimetry (DSC) thermogram as shown in FIG. 16 with ±0.4° C.;
(e) a thermogravimetric analysis (TGA) as shown in FIG. 17 with ±0.4% weight; and/or
an X-ray powder diffraction pattern comprising the following peaks: at about 11.4° 2-theta, at about 15.2° 2-theta and at about 22.9° 2-theta, as determined on a diffractometer using Cu-K? radiation at a wavelength of 1.5406 ?.

US Pat. No. 11,066,439

SYNTHESIS OF LIRAGLUTIDE

Biocon Limited, Electron...


1. A process for the preparation of liraglutide comprising the steps of,a) loading of C-terminal glycine to a resin solid-phase support in the presence of a coupling agent;
b) capping of the unreacted functional sites;
c) sequential coupling of N?- and side chain protected amino acids to prepare the backbone of liraglutide, in the presence of a coupling agent and an inorganic salt;
d) deprotecting the side chain protecting group of lysine;
e) coupling of glutamic acid and palmitic acid to the side chain of lysine in the presence of a coupling agent and an inorganic salt; and
f) obtaining crude liraglutide by removal of protective groups and cleavage of peptide from the resin,wherein the process comprises coupling of amino acids 9 to 13 at a temperature range of 30-45° C.,
wherein the inorganic salt is present in a catalytic amount and is selected from the group consisting of magnesium chloride, zinc chloride and copper chloride,
wherein step (c) comprises deprotection of the Fmoc group of each loaded amino acid using piperidine in DMF or a piperidine/DBU/DMF mixture, wherein after each Fmoc deprotection step there is a washing step using HOBt in DMF and deprotection of the methyltrityl protecting group of lysine.


US Pat. No. 11,066,696

QUANTUM METHOD FOR FLUORESCENCE BACKGROUND REMOVAL IN DNA MELTING ANALYSIS

UNIVERSITY OF UTAH RESEAR...


1. A method for analyzing a melting profile of a nucleic acid sample, comprisingmeasuring the fluorescence of the nucleic acid sample as a function of temperature to produce a raw melting curve having a melting transition, the nucleic acid sample comprising a nucleic acid and a molecule that binds the nucleic acid to form a fluorescently detectable complex, the raw melting curve comprising a background fluorescence signal and a nucleic acid sample signal; and
separating the background signal from the nucleic acid sample signal by use of a quantum algorithm to generate a corrected melting curve, the corrected melting curve comprising the nucleic acid sample signal;
wherein separating includes using the following equation:ln(I/Iref)=C(1/T?1/Tref)

where:
Tref is a reference temperature, and
Iref is the reference fluorescence intensity of the fluorescent dye at the reference temperature; and
wherein the separating step includes rescaling an original x-axis and an original y-axis from the raw melting curve to:x=(1/T?1/TREF)(° K) and
y=ln(I/IREF).


US Pat. No. 11,066,698

SMALL NUCLEIC ACID QUANTIFICATION USING SPLIT CYCLE AMPLIFICATION

Bio-Rad Laboratories, Inc...


1. A method of quantitating an amount of a target DNA template in a sample comprising:a) forming a plurality of mixture partitions, wherein the mixture partitions comprise:i) the target DNA template;
ii) a thermostable DNA dependent DNA polymerase; and
iii) a forward and a reverse amplification primer, wherein

the amplification primers comprise a 3? hybridization region that hybridizes to the target DNA template and primes template directed extension of the primer in the presence of the DNA dependent DNA polymerase;
the forward or the reverse amplification primer further comprises a 5? tail region that is not complementary to the target DNA template; and
b) performing end-point amplification of the target DNA template in the mixture partitions by a polymerase chain reaction, wherein the thermal cycling conditions comprise a first set of temperature cycles and a second set of temperature cycles, wherein the second set of temperature cycles comprises an annealing temperature that is at least 5° C. higher than an annealing temperature of the first set of temperature cycles, and wherein one or more 3? hybridization regions have a melting temperature (Tm) below the second annealing temperature; and
c) detecting the presence or absence of amplified target DNA template in the mixture partitions with an intercalating dye that produces a signal when intercalated in double stranded DNA and determining the fraction of partitions where the target DNA template is present; thereby quantifying the amount of target DNA template in the sample.

US Pat. No. 11,066,699

MICROFLUIDIC PROCESS FOR TREATING AND ANALYSING A SOLUTION CONTAINING A BIOLOGICAL MATERIAL AND CORRESPONDING MICROFLUIDIC CIRCUIT

ECOLE POLYTECHNIQUE, Pal...


1. A microfluidic process for partitioning a solution, said microfluidic process comprising the steps of:a. providing a microfluidic circuit, wherein microchannels suitable for containing fluids are defined, said circuit comprising at least one device for forming a plurality of droplets of a solution in a carrier fluid, and at least one storage zone, wherein:said at least one device for forming droplets further comprises said microchannels, wherein each of said microchannels comprise wall portions that diverge to detach a droplet of said solution under the effect of surface tension of said solution;

b. filling the microfluidic circuit with the carrier fluid;
c. flowing the solution in the carrier fluid through the microchannels of the microfluidic circuit; and
d. flowing additional carrier fluid through the microchannels of the microfluidic circuit after flowing the solution,thereby generating a plurality of droplets of said solution without losing a portion of the solution in microchannels.


US Pat. No. 11,066,700

NUCLEIC ACID COMPLEX PAIR, COMPETITIVE CONSTRUCT, AND PCR KIT USING THE SAME

MULTILEX, INC., Seoul (K...


1. A kit for a multiplexing PCR, the kit comprising:a first nucleic acid complex pair including a first nucleic acid complex and a second nucleic acid complex, wherein the first nucleic acid complex includes a first determinant, a first tag and a first label, and the second nucleic acid complex includes a second determinant, a second tag and a second label; and
a second nucleic acid complex pair including a third nucleic acid complex and a fourth nucleic acid complex, wherein the third nucleic acid complex includes a third determinant, a third tag and a third label, and the fourth nucleic acid complex includes a fourth determinant, a fourth tag and a fourth label,
wherein the first label is one of a first fluorophore-first quencher pair, and the second label is the other of the first fluorophore-first quencher pair,
wherein a fluorescence intensity emitted from the first fluorophore is adjusted by the first quencher when the first tag complementarily binds to the second tag,
wherein the third tag has a binding portion which complementarily binds to the fourth tag,
wherein the third label is one of a second fluorophore-second quencher pair, and the fourth label is the other of the second fluorophore-second quencher pair,
wherein a fluorescence intensity emitted from the second fluorophore is adjusted by the second quencher when the third tag complementarily binds to the fourth tag,
wherein a wavelength band of light emitted from the first fluorophore is substantially the same as a wavelength band of light emitted from the second fluorophore, and
wherein a length of the binding portion of the first tag is longer than a length of the binding portion of the third tag.

US Pat. No. 11,066,444

BMP-2-BINDING PEPTIDE AMPHIPHILE NANOFIBERS

Northwestern University, ...


1. A method of promoting spinal fusion comprising administering to a subject in need thereof a gel composition comprising:(a) bone morphogenetic protein-2 (BMP-2); and
(b) a BMP-2 binding peptide amphiphile comprising:(i) a hydrophobic non-peptidic segment;
(ii) a ?-sheet-forming peptide segment;
(iii) an acidic peptide segment; and
(iv) a BMP-2 binding peptide comprising the amino acid sequence of SEQ ID NO:1 (TSPHVPYGGGS);

wherein the hydrophobic non-peptidic segment is covalently attached to the N-terminus of the ?-sheet-forming peptide segment, wherein the C-terminus of the ?-sheet-forming peptide segment is covalently attached to the N-terminus of the acidic peptide segment, and wherein the C-terminus of the acidic peptide segment is covalently attached to the N-terminus of the BMP-2 binding peptide, wherein the BMP-2 binding peptide amphiphile is diluted by about 50% in the composition with a diluent peptide amphiphile, wherein the diluent peptide amphiphile comprises a hydrophobic non-peptidic segment, a ?-sheet forming segment, and an acidic peptide segment which matches the regions (i)-(iii) of the BMP-2 binding peptide amphiphiles, and wherein the diluent peptide amphiphile does not contain the amino acid sequence of SEQ ID NO:1.

US Pat. No. 11,066,703

COMPOSITIONS AND METHODS FOR IDENTIFYING NUCLEIC ACID MOLECULES

Natera, Inc., San Carlos...


1. A method for sequencing at least a portion of a population of sample nucleic acid molecules, wherein the method comprises:forming a reaction mixture comprising the population of sample nucleic acid molecules and a set of Molecular Index Tags (MITs), wherein the MITs are nucleic acid molecules, wherein the number of different MITs in the set of MITs is between 10 and 1,000, and wherein a ratio of the total number of sample nucleic acid molecules in the population of sample nucleic acid molecules to the number of different MITs in the set of MITs is at least 1,000:1;
attaching at least one MIT from the set of MITs to a sample nucleic acid molecule or segment thereof for at least 50% of the sample nucleic acid molecules to form a population of tagged nucleic acid molecules, wherein the at least one MIT is located 5? and/or 3? to the sample nucleic acid molecule or segment thereof on each tagged nucleic acid molecule and wherein the population of tagged nucleic acid molecules comprises at least one copy of each MIT of the set of MITs;
amplifying the population of tagged nucleic acid molecules to create a library of tagged nucleic acid molecules; and
determining the sequences of at least a portion of the tagged nucleic acid molecules by high-throughput sequencing.

US Pat. No. 11,066,704

METHODS FOR PREPARING TAGGING OLIGONUCLEOTIDES

SEEGENE, INC., Seoul (KR...


1. A method for preparing a tagging oligonucleotide comprising a targeting portion comprising a hybridizable-complementary nucleotide sequence to a target nucleic acid sequence and a tagging portion comprising a non-hybridizable-non-complementary nucleotide sequence to the target nucleic acid sequence, comprising:(a) selecting the hybridizable-complementary nucleotide sequence to the target nucleic acid sequence for the targeting portion and the non-hybridizable-non-complementary nucleotide sequence to the target nucleic acid sequence for the tagging portion; wherein the tagging portion comprises a first tagging part of 3-8 nucleotides in length adjacent to the targeting portion and a second tagging part of 4-40 nucleotides in length adjacent to the first tagging part; the non-hybridizable-non-complementary nucleotide sequence for the tagging portion is selected not to be hybridized with the target nucleic acid sequence; wherein a non-hybridizable-non-complementary nucleotide sequence of the first tagging part is selected by an independent non-complementarity level such that a sequence with a non-complementarity level satisfying a predetermined threshold value criterion is selected as the non-hybridizable-non-complementary nucleotide sequence of the first tagging part; and
(b) preparing the tagging oligonucleotide comprising (i) the targeting portion comprising the selected hybridizable-complementary nucleotide sequence and (ii) the tagging portion comprising the selected non-hybridizable-non-complementary nucleotide sequence.

US Pat. No. 11,066,449

MICROBIAL NANOWIRES WITH INCREASED CONDUCTIVITY AND REDUCED DIAMETERS

University of Massachuset...


1. An electrically conductive pilus comprising a plurality of modified Geobacter sulfurreducens PilA monomers, wherein each modified PilA monomer comprises an amino acid sequence that differs from SEQ ID NO: 19, the amino acid sequence of the wild-type Geobacter sulfurreducens PilA monomer, by the substitution of at least the amino acids at positions F51 and Y57 of SEQ ID NO: 19 with tryptophan, and wherein the electrically conductive pilus has greater conductivity than a wild-type Geobacter sulfurreducens pilus.
US Pat. No. 11,066,706

BLOOD BIOMARKERS FOR APPENDICITIS AND DIAGNOSTICS METHODS USING BIOMARKERS

The George Washington Uni...


1. A method of treating appendicitis in a human subject, comprising:a) obtaining a blood or serum sample from a human subject suffering from abdominal pain,
b) extracting RNA from said sample,
c) measuring the expression level of at least three RNA sequences selected from the group consisting of Chemokine C-X-C receptor 1, Interleukin 8 receptor ?, Fc frag of IgG receptor IIIb (CD16b), MHC class II DR beta 5, Leukocyte IgG-like receptor A3, Defensin alpha 1, Defensin alpha 1B, Defensin alpha 3, 18S ribosomal RNA, CDC14A, 28S ribosomal RNA, 60S acidic ribosomal protein P1, 40S ribosomal protein S26, Ribosomal protein L23, Ribosomal protein L37a, Ribosomal protein S28, Alkaline phosphatase, Carbonic anhydrase IV, Neuroblastoma breakpoint family 10, Ninjurin 1, Prokineticin 2, Superoxide dismutase 2, LOC100129902, LOC100131205, LOC100131905, LOC100132291, LOC100132394, LOC100132742, LOC100134364, LOC391370, LOC646785, LOC644191 and C50rf32 in the extracted RNA,
d) diagnosing the subject with appendicitis when at least three of said RNA sequences are differentially expressed by at least a 2.0 fold statistical difference with an uncorrected p<0.05 when compared to the expression level of said RNA sequences in a group not suffering from appendicitis, and
e) treating the diagnosed subject, wherein the treating comprises administering an antibiotic to said subject, removing said subject's appendix, or a combination thereof.

US Pat. No. 11,066,450

MODIFIED MENINGOCOCCAL FHBP POLYPEPTIDES

GLAXOSMITHKLINE BIOLOGICA...


1. A polypeptide comprising an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 5, wherein the amino acid sequence differs from SEQ ID NO: 5 by S32V, L123R, and E240A substitutions numbered relative to SEQ ID NO: 5.
US Pat. No. 11,066,707

DETECTION OF TARGET NUCLEIC ACID VARIANTS

SAGA DIAGNOSTICS AB, Lun...


1. A method for detection of the presence of a target nucleic acid sequence or detection of the presence of a variant sequence in a target nucleic acid sequence in a sample comprising the steps ofa) providing a sample comprising template nucleic acids,
b) providing a set of primers comprising at least a pair of primers specifically capable of amplification of the target nucleic acid sequence, wherein the set of primers at least comprises a primer-H and a primer-L, wherein the melting temperature of primer-H is at least 16° C. higher than the melting temperature of primer-L, and wherein primer-L contains a sequence complementary to a fragment of the elongation product of primer-H,
c) providing a nucleic acid polymerase having polymerase activity at an elongation temperature,
d) preparing partitioned PCR reactions each comprising a part of the sample, the set of primers, the nucleic acid polymerase, PCR reagents and optionally detection reagents,
e) performing an asymmetric incremental polymerase reaction (AIPR) comprising the steps of:i) incubating the partitioned PCR reactions at a denaturation temperature, thereby denaturing DNA to single-stranded molecules,
ii) incubating the partitioned PCR reactions at a high annealing temperature allowing annealing of primer-H, but not of primer-L,
iii) optionally incubating the partitioned PCR reactions at the elongation temperature,
iv) optionally repeating steps i to iii,

f) performing a polymerase chain reaction (PCR) comprising the steps of:1) incubating the partitioned PCR reactions from step
e) at a denaturation temperature, thereby denaturing DNA to single-stranded molecules,
2) incubating the PCR at a low annealing temperature allowing annealing of both primer-H and primer-L,
3) incubating the PCR at the elongation temperature thereby allowing extension of all annealed primers,
4) optionally repeating steps 1 to 3,

g) detecting whether the PCR product comprises the target nucleic acid sequence or the variant sequence in the target nucleic acid sequence.

US Pat. No. 11,066,451

METHODS FOR PURIFYING CLOSTRIDIAL NEUROTOXIN

IPSEN BIOPHARM LIMITED, ...


1. A method of producing the active di-chain form of a clostridial neurotoxin, the method comprising:(a) contacting a cation exchange resin with a composition comprising a single-chain clostridial neurotoxin, wherein the contacting step is performed at a pH of from 7.3 to 9.5;
(b) separating the clostridial neurotoxin from the cation exchange resin and
(c) contacting the separated clostridial neurotoxin with a protease that cleaves the polypeptide sequence of the clostridial neurotoxin under conditions suitable for the cleavage, thereby activating it to produce the active di-chain form of the clostridial neurotoxin,

wherein the step (a) occurs before the step (b).
US Pat. No. 11,066,708

COMPOSITIONS AND METHODS FOR SCREENING AND DIAGNOSIS OF PROSTATE CANCER

DANA-FARBER CANCER INSTIT...


1. A method of treating prostate cancer in a subject in need thereof, comprising:(a) comparing an expression level of KDM5D in a sample from the subject to an expression level of KDM5D in a control sample, and
(b) when the expression level of KDM5D in the sample from the subject is the same as, or higher than, the expression level of KDM5D in the control sample, then administering a taxane without androgen deprivation therapy (ADT) or administering ADT without a taxane to the subject, and when the expression level of KDM5D in the sample from the subject is lower than the expression level in the control sample, then administering a taxane and ADT to the subject.

US Pat. No. 11,066,452

ANTIBODY BINDING NANOFIBRILS


1. An antibody binding nanofibril obtained by co-fibrillation of carrier protein and carrier-Z fusion protein at a molar ratio selected within an interval of from 1:0.20 to 1:0.90, wherein said carrier-Z fusion protein is fusion protein between a carrier protein and an antibody binding Z domain of a protein, wherein the carrier protein is a soluble protein monomer that aggregates into oligomers and further into fibrils and fibers in a molecular self-assembly process.
US Pat. No. 11,066,709

METHODS FOR DIAGNOSING AND TREATING CANCER BY MEANS OF THE EXPRESSION STATUS AND MUTATIONAL STATUS OF NRF2 AND DOWNSTREAM TARGET GENES OF SAID GENE

Genentech, Inc., South S...


1. A method of treating a subject having a cancer, the method comprising:(a) determining the mRNA expression of NRF2 in a sample obtained from the subject, wherein the subject expresses NRF2 comprising an exon 2-deleted NRF2 splice variant, and wherein the presence of the exon 2-deleted NRF2 splice variant identifies the subject as likely to respond to a NRF2 pathway antagonist; and
(b) administering to the subject a therapeutically effective amount of a NRF2 pathway antagonist.

US Pat. No. 11,065,676

METHOD FOR PRODUCING CASTING MOLDS, CORES AND BASIC MOLD MATERIALS REGENERATED THEREFROM


1. A process for producing casting molds, cores and mold base materials regenerated therefrom, comprising the following steps for production of a casting mold or a core:providing or producing a molding material mixture comprisinga mold base material
a solution or dispersion comprising waterglass
0.1% to 3% by weight of particulate amorphous silicon dioxide

and, to facilitate the breakdown and/or to increase the regeneratability of the casting mold or the core,one or more particulate sheet silicates in a total amount of 0.05% to 0.4% by weight, where the d90 of the total amount of the sheet silicates is less than 45 ?m,

where the percentages are each based on the total mass of the molding material mixture,
shaping the molding material mixture,
curing the molding material mixture by chemical reaction of constituents of the molding material mixture with one another, so as to result in the casting mold or the core.

US Pat. No. 11,066,453

IMMUNOGENIC COMPOSITIONS CONTAINING BACTERIAL OUTER MEMBRANE VESICLES AND THERAPEUTIC USES THEREOF

BIOMVIS SRL, Siena (IT)


1. An isolated bacterial outer membrane vesicle comprising a fusion protein, wherein the fusion protein comprises an isolated bacterial protein fused to one or more copies of an immunogenic tumor antigen protein, wherein the isolated bacterial protein is selected from the group consisting of Neisseria meningitidis factor H binding protein (fHbp) of SEQ ID NO: 1, Neisseria meningitidis NHBA of SEQ ID NO: 109, Escherichia coli outer membrane protein-F (OmpF) of SEQ ID NO: 3, and Aggregatibacter actinomycetemcomitans factor H binding protein (Aa-fHbp) of SEQ ID NO: 110.
US Pat. No. 11,066,710

METHOD FOR DETECTING AN INCREASED RISK OR INCIDENCE OF COLORECTAL CANCER

Siemens Healthcare Diagno...


1. A method of treating an individual at risk of or suffering from colorectal cancer, the method comprising administering to the individual a therapeutically effective amount of a chemotherapeutic agent for treating colorectal cancer, wherein, prior to administration, a sample from the individual has been determined to have:(i) a level of RNA transcribed from the COL10A1 gene that is increased at least 10% relative to a level of RNA transcribed from the COL10A1 gene in a reference sample, and a level of RNA transcribed from the ABHD2 gene that is increased at least 10% relative to a level of RNA transcribed from the ABHD2 gene in a reference sample; or
(ii) a level of RNA transcribed from the MMP11 gene that is increased at least 10% relative to a level of RNA transcribed from the MMP11 gene in a reference sample, and a level of RNA transcribed from the ABHD2 gene that is increased at least 10% relative to a level of RNA transcribed from the ABHD2 gene in a reference sample.

US Pat. No. 11,066,454

COMPOSITIONS COMPRISING VARIANTS AND FUSIONS OF FGF19 POLYPEPTIDES

NGM BIOPHARMACEUTICALS, I...

wherein the peptide has at least one amino acid substitution to the RP sequence of the EIRPD sequence (amino acids 97-101 of SEQ ID NO:141),
wherein the at least one amino acid substitution is (i) a substitution of the R residue to L residue, (ii) a substitution of the P residue to E residue, or (iii) a substitution of the R residue to L residue and a substitution of the P residue to E residue.
US Pat. No. 11,066,711

BIOMARKERS FOR PREDICTING CLOSTRIDIUM DIFFICILE INFECTION TREATMENT OUTCOME

Mayo Foundation for Medic...


1. A method for treating a Clostridium difficile infection (CDI) in a mammal, the method comprising:detecting a gut microbiota panel in a fecal sample obtained from the mammal, wherein the gut microbiota panel comprises Veillonella, Enterobacteriaceae, Streptococcus, Parabacteroides, and Lachnospiraceae;
administering advanced CDI treatment to the mammal if two or more of Veillonella, Enterobacteriaceae, Streptococcus, Parabacteroides, and Lachnospiraceae in the panel are increased relative to a control gut microbiota panel, wherein the advanced CDI treatment is selected from the group consisting of fecal transplantation, immunoglobulin therapy, and defined microbial consortia.

US Pat. No. 11,066,455

TMEM100 PEPTIDES AND VARIANTS THEREOF AND THEIR USE IN TREATING OR PREVENTING DISEASES OR CONDITIONS

The Johns Hopkins Univers...


1. A method for treating or preventing a condition associated with TRPA1 function or for which reduced TRPA1 activity can reduce the severity, comprising administering an effective amount of a Tmem100 mutant polypeptide, comprising administering to the cell an effective amount of a Tmem100 mutant polypeptide, wherein the Tmem100 mutant polypeptide comprises an amino acid sequence selected from the group consisting of: SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 17, thereby inhibiting TRPA1 function in the cell; ora method of preventing, treating, or alleviating symptoms of a disease or condition associated with TRPA1 function or for which reduced TRPA1 activity can reduce the severity, comprising administering to a subject in need thereof a Tmem100 mutant polypeptide, wherein the Tmem100 mutant polypeptide comprises an amino acid sequence selected from the group consisting of: SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 17, thereby inhibiting TRPA1 function in the cell; or
a method of inhibiting TRPA1 function in a cell, comprising administering to the cell an effective amount of a Tmem100 mutant polypeptide, wherein the Tmem100 mutant polypeptide comprises an amino acid sequence selected from the group consisting of: SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 17, thereby inhibiting TRPA1 function in the cell.

US Pat. No. 11,066,712

RAPID VIRAL ASSAY


1. A method for rapid, highly specific and sensitive, detection and quantification of a virus in an individual suspected of being infected with a virus by observing binding with a host receptor protein of a viral substrate of the virus contained in a specimen taken from the individual, comprising the steps of:coating a plurality of microtiter wells with a host receptor protein contained in a coating buffer;
incubating the plurality of microtiter wells overnight;
washing the microtiter wells;
adding a blocking solution to the plurality of microtiter wells;
washing the plurality of microtiter wells three times;
adding the viral substrate to the plurality of microtiter wells;
incubating the plurality of microtiter wells for 20 minutes;
washing the plurality of microtiter wells three times;
adding an antibody directed against the viral substrate to the plurality of microtiter wells;
incubating the plurality of microtiter wells for 20 minutes;
adding a horseradish peroxidase (HRP)-conjugated antibody directed against the antibody to the plurality of microtiter wells;
incubating the plurality of microtiter wells for 20 minutes;
washing the plurality of microtiter wells three times;
adding a TMB solution to the plurality of microtiter wells;
adding a Stop solution to the plurality of microtiter wells; and
detecting the viral substrate in the microtiter wells by observing those microtiter wells that undergo a color change or quantifying the concentration of the viral substrate by reading optical density at 450 nm, wherein the method following the overnight incubation is completed by a user in about one hour.

US Pat. No. 11,066,456

COMPOSITIONS COMPRISING TREM2 AND METHODS OF USE THEREOF

Washington University, S...


1. A method of activating a microglia cell in a subject with reduced or absent TREM2 intracellular signaling, the method comprising administering to the subject a composition comprising an isolated polypeptide comprising at least one TREM2 or fragment thereof and a targeting moiety, wherein the targeting moiety is an Fc fragment and wherein the Fc fragment binds to an Fc receptor on the microglia thereby activating the microglia by triggering intracellular signaling similar to those induced by DAP12.
US Pat. No. 11,066,457

CONSTRUCTION OF CHIMERIC ANTIGEN RECEPTOR TARGETING CD20 ANTIGEN AND ACTIVITY IDENTIFICATION OF ENGINEERED T CELLS THEREOF

CELLULAR BIOMEDICINE GROU...


1. A method of treating a B-cell malignancy, the method comprising administering a T cell expressing a chimeric antigen receptor (CAR) to a subject in need thereof, wherein the CAR comprises an anti-CD20 antigen binding region comprising:(i) a heavy chain variable region (VH) having an amino acid sequence set forth in SEQ ID NO: 7, and
(ii) a light chain variable region (VL) having an amino acid sequence set forth in SEQ ID NO: 11,
wherein VH is located at the N-terminus of VL,
wherein the CAR comprises an amino acid sequence set forth in SEO ID NO: 5.

US Pat. No. 11,066,458

VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION

REGENERON PHARMACEUTICALS...


1. A glass vial comprising an ophthalmic formulation suitable for intravitreal administration comprising:a vascular endothelial growth factor (VEGF) antagonist fusion protein,
an organic co-solvent,
a buffer, and
a stabilizing agent;
wherein said VEGF antagonist fusion protein is glycosylated and comprises an immunoglobulin-like (Ig) domain 2 of a first VEGF receptor that is human Flt1 and Ig domain 3 of a second VEGF receptor selected from the group consisting of human Flk1 and human Flt4, and a multimerizing component; and
wherein at least 98% of said VEGF antagonist fusion protein is present in native conformation following storage at 5° C. for two months as measured by size exclusion chromatography.

US Pat. No. 11,066,716

STEEL SHEET AND METHOD FOR PRODUCING THE SAME

JFE Steel Corporation, T...


1. A steel sheet comprising:a composition containing, in mass %,C: 0.07% or more and 0.20% or less,
Si: 0.60% or more and 1.65% or less,
Mn: 1.8% or more and 3.5% or less,
P: 0.05% or less,
S: 0.005% or less,
Al: 0.08% or less,
N: 0.0060% or less, and
the balance being Fe and unavoidable impurities;

a microstructure containing, by area fraction, ferrite of 30% or less (including 0%), tempered martensite of 70% or more (including 100%), and the balance other than the ferrite and the tempered martensite including 10% or less (including 0%) in total,the tempered martensite having an average grain size of is of 5 ?m or less,
the tempered martensite having iron-based carbides, which have an average particle size of 100 nm or less, precipitated on grain boundaries thereof, and
the tempered martensite containing, in terms of atomic concentration, 5% or more in total of Si and Mn on the grain boundaries of the tempered martensite; and

a tensile strength of 900 MPa or higher.

US Pat. No. 11,066,460

PHAGE DISPLAY VECTORS AND METHODS OF USE

Eli Lilly and Company, I...


1. A type 33 bacteriophage M13 vector comprising a first polynucleotide sequence encoding a polypeptide sequence as given by SEQ ID NO:1 and a second polynucleotide sequence encoding a polypeptide sequence as given by SEQ ID NO:2.
US Pat. No. 11,065,684

MAGNESIUM OXIDE POWDER, PRODUCTION METHOD THEREFOR, THERMALLY-CONDUCTIVE RESIN COMPOSITION, THERMALLY-CONDUCTIVE GREASE, AND THERMALLY-CONDUCTIVE COATING MATERIAL

UBE MATERIAL INDUSTRIES, ...


1. A magnesium oxide powder having: a median diameter (D50) of 5 to 100 ?m; a MgO purity of 98% to 99.9% by mass; a Ca compound content of 0.1 to 2% by mass in terms of CaO; and when the magnesium oxide powder is immersed in pure water and allowed to stand at 95° C. for 24 hours, a mass ratio of calcium ions to magnesium ions, Ca/Mg, in an aqueous solution of 1 to 6,wherein when the magnesium oxide powder is dispersed in an aqueous sulfuric acid solution controlled to pH=3, 1800 seconds or more is taken until sulfuric acid equivalent to 50% of the magnesium oxide powder is consumed.

US Pat. No. 11,066,462

METHOD FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS

Citryll B.V., Oss (NL)


1. A method for the treatment of a subject having idiopathic pulmonary fibrosis, the method comprising:obtaining an antibody specifically reactive with a citrullinated epitope on the N-terminus of deiminated histone H2A or H4; and
administering the antibody to the subject,
wherein the antibody comprises a heavy chain CDR1 domain comprising SEQ ID NO: 5, a heavy chain CDR2 domain comprising SEQ ID NO: 6, a heavy chain CDR3 domain comprising SEQ ID NO: 7, a light chain CDR1 domain comprising SEQ ID NO: 8, a light chain CDR2 domain comprising SEQ ID NO: 9, and a light chain CDR3 domain comprising SEQ ID NO: 10.

US Pat. No. 11,065,686

METHOD FOR SINTERING METALS, NON-OXIDE CERAMICS AND OTHER OXIDATION-SENSITIVE MATERIALS

FORSCHUNGSZENTRUM JUELICH...


1. A method for sintering metallic and/or non-oxide ceramic components, the method comprising:completely encapsulating, in a metal halide salt, a green body comprising at least one metallic and/or non-oxide ceramic powder;
after the encapsulating the green body in the metal halide salt, compressing the encapsulated green body so as to be gastight;
adding the compressed, encapsulated green body directly to a molten metal halide salt bath:
heating, in the presence of oxygen up to sintering temperatures, the compressed, encapsulated green body in the molten metal halide salt bath; and
at least partially dissolving, after cooling, the metal halide salt in a liquid so that a sintered metallic and/or non-oxide ceramic component, formed from the green body, can be removed.

US Pat. No. 11,066,463

ANTI-POLYUBIQUITIN ANTIBODIES AND METHODS OF USE

Genentech, Inc., South S...


1. A method of separating K11-linked polyubiquitinated protein from non-K11-linked polyubiquitinated protein in a sample, comprising contacting the sample with an antibody that binds K11-linked polyubiquitin, wherein the antibody comprises an HVR-L1 sequence selected from SEQ ID NOs: 2 and 57 to 60, an HVR-L2 sequence selected from SEQ ID NOs: 3 and 61, an HVR-L3 sequence of SEQ ID NO: 4, an HVR-H1 sequence selected from SEQ ID NOs: 6 to 11, an HVR-H2 sequence selected from SEQ ID NOs: 12 to 17 and 67, and an HVR-H3 sequence selected from SEQ ID NOs: 18 to 23, 68 and 69.
US Pat. No. 11,066,464

ANTI-MALARIAL ANTIBODIES THAT BIND CIRCUMSPOROZOITE PROTEIN

KYMAB LIMITED, Cambridge...


1. An isolated antibody that specifically binds the circumsporozoite protein (CSP) of Plasmodium falciparum, comprising the heavy and light chain complementarity determining regions of antibody 666 (SEQ ID Nos: 3-5 and 8-10, respectively), antibody 667 (SEQ ID Nos: 13-15 and 18-20, respectively), antibody 668 (SEQ ID Nos: 23-25 and 28-30, respectively) or antibody 669 (SEQ ID Nos: 33-35 and 38-40, respectively).
US Pat. No. 11,066,721

HIGH-STRENGTH HOT-DIP COATED HOT-ROLLED STEEL SHEET AND METHOD FOR MANUFACTURING THE SAME

JFE STEEL CORPORATION, T...


1. A high-strength hot-dip coated hot-rolled steel sheet comprising:a hot-rolled steel sheet having a chemical composition including:C: 0.02% or more and 0.30% or less, by mass %,
Si: 0.01% or more and 1.0% or less, by mass %,
Mn: 0.3% or more and 2.5% or less, by mass %,
P: 0.08% or less, S: 0.02% or less, by mass %,
Al: 0.001% or more and 0.20% or less, by mass %, and
Fe and inevitable impurities; and

a hot-dip coating layer formed on a surface of the hot-rolled steel sheet, wherein:
the high-strength hot-dip coated hot-rolled steel sheet has a tensile strength of 590 MPa or more, and
the surface of the hot-rolled steel sheet has:an arithmetic average roughness Ra of 2.0 ?m or less, and

an average residual stress ? in an ?-Fe (211)-plane that satisfies a relationship ?250 MPa????30 MPa.

US Pat. No. 11,066,466

INHIBITION OF SCUBE2, A NOVEL VEGFR2 CO-RECEPTOR, SUPPRESSES TUMOR ANGIOGENESIS

ACADEMIA SINICA, Taipei ...


1. An isolated anti-signal peptide-complement protein C1r/C1s, Uegf, and Bmp1 (CUB)-epidermal growth factor (EGF) domain-containing protein 2 (SCUBE2) monoclonal antibody or a binding fragment thereof, comprising a heavy chain variable domain (VH) and a light chain variable domain (VL), wherein:the VH comprises a complementarity determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO: 19, a CDR2 comprising the amino acid sequence of SEQ ID NO: 20, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 21; and the VL comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 22, a CDR2 comprising the amino acid sequence of SEQ ID NO: 23, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 24; and further wherein:
the isolated anti-SCUBE2 monoclonal antibody or binding fragment thereof specifically binds to a target domain with an amino acid (a.a.) sequence ranging from a.a. 441-659 of SCUBE2 (SEQ ID NO: 66).

US Pat. No. 11,064,658

METHOD FOR INDUCING PLANTS TO INCREASE THEIR FLAVONOID COMPOUND CONTENT

INDUSTRIAL TECHNOLOGY RES...


1. A method for inducing plants to increase their flavonoid compound content, comprising:performing an induction culture on a young shoot or an adult of a living plant, wherein flavonoid compound content of the young shoot or the adult of the living plant which has been subjected to the induction culture is higher than that of a young shoot or an adult of a living plant which is not subjected to the induction culture, and
wherein the induction culture comprises:
a metal ion stimulation procedure comprising culturing the young shoot or the adult of the living plant in a culture environment with metal ion stimulation; and
an ultraviolet irradiation procedure to irradiate the young shoot or the adult of the living plant with ultraviolet,
wherein the culture environment with metal ion stimulation contains a metal ion used for stimulating the living plant, and the concentration of the metal ion used for stimulating the living plant is 5 ?M-50 ?M.

US Pat. No. 11,066,467

COMPOSITIONS AND METHODS FOR TREATING ISCHEMIC HEART DISEASE

MHS CARE-INNOVATION LLC, ...


1. A method of treating ischemic heart disease or clinical manifestations thereof in a human having ischemic heart disease, comprising:administering to a person a composition comprising a pharmaceutically effective amount of a molecular antagonist of human gastric inhibitory polypeptide (GIP),
wherein the molecular antagonist comprises a light chain variable domain and a heavy chain variable domain;
wherein the light chain variable domain comprises a first complementarity determining region (CDR) with 100% identity to an amino acid sequence of SEQ ID NO: 20, a second CDR with 100% identity to an amino acid sequence of SEQ ID NO: 21 or SEQ ID NO: 22 or SEQ ID NO: 23, and a third CDR with 100% identity to an amino acid sequence of SEQ ID NO: 24; and
wherein the heavy chain variable domain comprises a first CDR with 100% identity to an amino acid sequence of SEQ ID NO: 31, a second CDR with 100% identity to an amino acid sequence of SEQ ID NO: 32, and a third CDR with 100% identity to an amino acid sequence of SEQ ID NO: 33.

US Pat. No. 11,066,468

IMMUNOCONJUGATES WITH AN INTRACELLULARLY-CLEAVABLE LINKAGE

Immunomedics, Inc., Morr...


1. A method of delivering SN-38 to a cell that expresses CEACAM5 comprising administering to the cell an immunoconjugate comprising (i) an antibody or an antigen-binding fragment thereof, wherein said antibody or fragment thereof binds to a tumor-associated antigen CEACAM5; (ii) six or more molecules of SN-38 covalently attached to the antibody or antibody fragment thereof; and (iii) a linker attaching the SN-38 to the antibody or fragment thereof.
US Pat. No. 11,066,469

NATRIURETIC PEPTIDE RECEPTOR 1 ANTIBODIES AND METHODS OF USE

NOVARTIS AG, Basel (CH)


1. An isolated anti-natriuretic peptide receptor 1 (NPR1) antibody or antigen binding fragment, wherein the antibody or antigen binding fragment comprises three heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3) and three light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3) selected from:(I) SEQ ID NO: 28 (HCDR1), SEQ ID NO: 119 (HCDR2), SEQ ID NO: 30 (HCDR3), SEQ ID NO: 41 (LCDR1), SEQ ID NO: 42 (LCDR2), and SEQ ID NO: 134 (LCDR3);
(II) SEQ ID NO: 31 (HCDR1), SEQ ID NO: 119 (HCDR2), SEQ ID NO: 30 (HCDR3), SEQ ID NO: 41 (LCDR1), SEQ ID NO: 42 (LCDR2), and SEQ ID NO: 134 (LCDR3);
(III) SEQ ID NO: 32 (HCDR1), SEQ ID NO: 120 (HCDR2), SEQ ID NO: 30 (HCDR3), SEQ ID NO: 44 (LCDR1), SEQ ID NO: 45 (LCDR2), and SEQ ID NO: 135 (LCDR3); and
(IV) SEQ ID NO: 34 (HCDR1), SEQ ID NO: 121 (HCDR2), SEQ ID NO: 36 (HCDR3), SEQ ID NO: 47 (LCDR1), SEQ ID NO: 45 (LCDR2), and SEQ ID NO: 134 (LCDR3).

US Pat. No. 11,066,470

HUMANIZED ANTIBODIES WITH INCREASED STABILITY

INNATE PHARMA, Marseille...


1. Recombinant nucleic acids encoding an antibody or antibody fragment that binds to a KIR3DL2 polypeptide, selected from the group consisting of:(a) an antibody or antibody fragment comprising respectively a VH and VL region comprising the amino acid sequence of SEQ ID NOS: 31 and 25,
(b) an antibody or antibody fragment comprising respectively a VH and VL region comprising the amino acid sequence of SEQ ID NOS: 31 and 26,
(c) an antibody or antibody fragment comprising respectively a VH and VL region comprising the amino acid sequence of SEQ ID NOS: 14 and 9, and
(d) an antibody or antibody fragment comprising respectively a VH and VL region comprising the amino acid sequence of SEQ ID NOS: 15 and 9.

US Pat. No. 11,066,471

ANTIBODIES TO MICA AND MICB PROTEINS

Novelogics Biotechnology ...


1. An isolated antibody comprising a CDR L1, CDR L2 and CDR L3 in the light chain variable region amino acid sequence of SEQ ID NO:25, and a CDR H1, CDR H2 and CDR H3 in the heavy chain variable region amino acid sequence of SEQ ID NO:29, wherein the antibody binds specifically to soluble MICA (sMICA) or soluble MICB (sMICB) protein.
US Pat. No. 11,066,728

NI-BASED HEAT-RESISTANT ALLOY

TOHOKU TECHNO ARCH CO., L...


1. A polycrystalline Ni-based heat-resistant alloy comprising Ir: 5.0 mass % or more and 50.0 mass % or less, Al: 1.0 mass % or more and 8.0 mass % or less, W: 5.0 mass % or more and 25.0 mass % or less, and balance Ni, having an L12-structured ?? phase present in the matrix, andincluding at least one of Zr: 0.8 mass % or more and 2.0 mass % or less and Hf: 1.0 mass % or more and 2.0 mass % or less.

US Pat. No. 11,066,472

METHODS OF TREATING CARDIOVASCULAR DISEASE WITH AN ANTI-ASGR ANTIBODY OR BINDING FRAGMENTS THEREOF

Amgen Inc., Thousand Oak...


1. A method of treating or preventing a cardiovascular disease comprising administering to a patient in need thereof a therapeutically effective dose of an isolated antigen binding protein that binds to ASGR-1 (asialoglycoprotein receptor 1), wherein the isolated antigen binding protein is a neutralizing antibody or a neutralizing antigen binding fragment thereof.
US Pat. No. 11,066,473

GALECTIN-10 ANTIBODIES

argenx IIP BV, Ghent (BE...


1. An antibody or antigen binding fragment thereof which binds to galectin-10, wherein the antibody or antigen binding fragment thereof comprises a combination of a heavy chain variable domain (VH) and a light chain variable domain (VL),wherein the VH comprises the amino acid sequence of SEQ ID NO: 194, and the VL comprises the amino acid sequence of SEQ ID NO: 195.

US Pat. No. 11,066,474

ANTI-TRKB MONOCLONAL ANTIBODIES AND METHODS OF USE

REGENERON PHARMACEUTICALS...


1. An isolated antibody or antigen-binding fragment thereof that binds specifically to tropomyosin receptor kinase B (TrkB), wherein the antibody or antigen-binding fragment thereof comprises a set of six complementarity determining regions (HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3) comprising an HCDR1 comprising the amino acid sequence of SEQ ID NO:4, an HCDR2 comprising the amino acid sequence of SEQ ID NO:6, an HCDR3 comprising the amino acid sequence of SEQ ID NO:8, an LCDR1 comprising the amino acid sequence of SEQ ID NO:12, an LCDR2 comprising the amino acid sequence of SEQ ID NO:14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:16.
US Pat. No. 11,064,666

QTLS CONFERRING RESISTANCE TO POTYVIRUSES IN WATERMELON

RIJK ZWAAN ZAADTEELT EN Z...


1. A watermelon plant of the species Citrullus lanatus subsp. lanatus that produces fruits with red flesh and comprisesa) a QTL3 located on chromosome 3, which confers resistance to a potyvirus, wherein QTL3 is as found in a watermelon plant, representative seed of which was deposited under deposit accession number NCIMB 42535, and wherein QTL3 is located between molecular marker M2112, having SEQ ID NO:89 or SEQ ID NO:90, and molecular marker M2122, having SEQ ID NO:97 or SEQ ID NO:98, and is linked to the SNP at position 101 of SEQ ID NO:94 of molecular marker M2116, and
b)i) QTL1, or
b)ii) QTL2, or
b)iii) QTL1 and QTL2, wherein:
QTL1 located on chromosome 8,
QTL2 located on chromosome 6,
each of QTL1 and QTL2 confer resistance to a potyvirus,
QTL1 is as found in a watermelon plant, representative seed of which was deposited under deposit number NCIMB 42537, and wherein QTL1 is located between molecular marker M2382, having SEQ ID NO:1 or SEQ ID NO:2, and molecular marker M2386, having SEQ ID NO:41 or SEQ ID NO:42, and is linked to the SNP at position 101 of SEQ ID NO:18 of molecular marker M2384, and
QTL2 is as found in a watermelon plant, representative seed of which was deposited under deposit number NCIMB 42536, and wherein QTL2 is located between molecular marker M2283, having SEQ ID NO:43 or SEQ ID NO:44, and molecular marker M1567, having SEQ ID NO:87 or SEQ ID NO:88 and is linked to the SNP at position 101 of SEQ ID NO:74 of molecular marker M4952.

US Pat. No. 11,066,475

CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR B-CELL MATURATION ANTIGEN AND ENCODING POLYNUCLEOTIDES

Juno Therapeutics, Inc., ...


1. A polynucleotide encoding a chimeric antigen receptor, the polynucleotide comprising a nucleic acid sequence encoding: (a) an extracellular antigen-binding domain comprising a single-chain variable fragment (scFv) comprising a variable heavy chain (VH) region and a variable light chain (VL) region that specifically binds B cell maturation antigen (BCMA); (b) a spacer encoded by the nucleic acid sequence set forth in SEQ ID NO:622; (c) a transmembrane domain; and (d) an intracellular signaling region.
US Pat. No. 11,064,667

BROCCOLI TYPE HAVING CURDS WITH DETACHED FLORETS

SEMINIS VEGETABLE SEEDS, ...


1. A seed of a broccoli plant capable of producing a plant comprising a curd having florets, wherein the traits of said florets on said curd comprise:an average of more than 85% of the flower buds on said florets having a color score in the green range on the Royal Horticultural Society color chart selected from the group consisting of 137A, 137B, 138A, and 138B, and at least 50% of said florets on said curd are not touching another floret on said curd; and

wherein said traits are obtainable from a broccoli line selected from the group consisting of 550478, a representative sample of seed of said line having been deposited with the NCIMB under NCIMB Accession No. 41416; 550479, a representative sample of seed of said line having been deposited with the NCIMB under NCIMB Accession No. 41415; 550385, a representative sample of seed of said line having been deposited with the NCIMB under NCIMB Accession No. 41417; and 550198, a representative sample of seed of said line having been deposited with the NCIMB under NCIMB Accession No. 41418.
US Pat. No. 11,066,476

ASYMMETRIC BISPECIFIC ANTIBODY

SHANGHAI TONGJI HOSPITAL,...


1. An asymmetric bispecific antibody, comprising:a first chain comprising, in order from the N-terminus to the C-terminus, a light chain variable region (VL) and a light chain constant region (CL);
a second chain comprising, in order from the N-terminus to the C-terminus, a heavy chain variable region (VH), a heavy chain constant region, and a single-chain variable fragment (scFv), whereinthe heavy chain constant region of the second chain comprises a CH1 domain and a Fc region,
the scFv of the second chain comprises, in order from the N-terminus to the C-terminus, a heavy chain variable region and a light chain variable region against a second antigen or epitope, or in order from the N-terminus to the C-terminus, a light chain variable region and a heavy chain variable region against a second antigen or epitope,
the VL and the CL of the first chain and the VH and the CH1 domain of the second chain together constitute an antigen-binding fragment (Fab) against a first antigen or epitope; and

a third chain comprising a heavy chain Fc region, wherein the heavy chain Fc region comprises an antibody hinge region, CH2 and CH3;
the light chain variable region of the first chain and the heavy chain variable region of the second chain specifically bind to the first antigen or epitope, and the scFv of the second chain specifically binds to the second antigen or epitope; and
the first antigen or epitope is CD89, and the VL of the first chain comprises the following CDRs: CDR1 having a sequence of SEQ ID NO: 9, CDR2 having a sequence of SEQ ID NO: 10, and CDR3 having a sequence of SEQ ID NO: 11, and the VH of the second chain comprises the following CDRs: CDR1 having a sequence of SEQ ID NO: 12, CDR2 having a sequence of SEQ ID NO: 13, and CDR3 having a sequence of SEQ ID NO: 14.

US Pat. No. 11,064,668

MELON VARIETY NUN 76307 MEM

NUNHEMS B.V., Nunhem (NL...


1. A plant, plant part, or seed of melon variety NUN 76307 MEM, wherein a representative sample of seed of said melon variety has been deposited under Accession Number NCIMB 43705.
US Pat. No. 11,066,477

MONOCLONAL ANTIBODY AGAINST MELK AND UTILIZATION THEREOF

ONCOTHERAPY SCIENCE, INC....


1. An antibody or antigen-binding fragment thereof, which can bind MELK protein or a partial peptide thereof, and which comprises both of:a heavy chain variable region comprising
a CDR1 comprising the amino acid sequence of SEQ ID NO: 1,
a CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and
a CDR3 comprising the amino acid sequence of SEQ ID NO: 3, and a light chain variable region comprising
a CDR1 comprising the amino acid sequence of SEQ ID NO: 4,
a CDR2 comprising the amino acid sequence of SEQ ID NO: 5, and
a CDR3 comprising the amino acid sequence of SEQ ID NO: 6.

US Pat. No. 11,066,734

THERMAL SPRAY SLURRY, THERMAL SPRAY COATING AND METHOD FOR FORMING THERMAL SPRAY COATING

FUJIMI INCORPORATED, Kiy...


1. A thermal spray slurry comprising:a dispersion medium;
a dispersing agent; and
thermal spray particles formed of at least one material selected from the group consisting of a ceramic, a cermet, and a metal, wherein:
the ceramic is an oxide-based ceramic, carbide-based ceramic, nitride-based ceramic, or boride-based ceramic;
the dispersion medium comprises water and/or at least one organic solvent;
800 mL of the thermal spray slurry contains A kg of the thermal spray particles;
when 800 mL of the thermal spray slurry in which the thermal spray particles are dispersed is supplied at a flow rate of 35 mL/min to a horizontally-placed tube and collected, the collected slurry contains B kg of the thermal spray particles; and
the slurry has a supply efficiency index If of 70% or higher, determined by the next equation If (%)=B/A×100.

US Pat. No. 11,064,669

SOYBEAN CULTIVAR CW1660188

Syngenta Crop Protection ...


1. A plant, a plant part, or a seed of soybean variety CW1660188, wherein a representative sample of seed of said soybean variety CW1660188 has been deposited under ATCC Accession Number PTA-125577.
US Pat. No. 11,065,183

CURABLE COMPOSITION

TOKUYAMA DENTAL CORPORATI...


1. A curable composition comprising a polymerizable monomer (A); spherical particles (B) having an average primary-particle diameter in a range of 230 nm to 1,000 nm; a polymerization initiator (C), and inorganic particles (D) having an average primary-particle diameter of less than 100 nm, wherein90% or more of individual particles constituting the spherical particles (B) lies in a range of ±5% based on the average primary-particle diameter,
the polymerizable monomer (A) and the spherical particles (B) satisfy requirement (X1) represented by the following formula (1):nP
in formula (1), nP represents a refractive index at 25° C. of a polymer obtained by polymerizing the polymerizable monomer (A); and nF represents a refractive index at 25° C. of the spherical particles (B), and
when a 1 mm-thick cured product is formed from the curable composition and the Y value (Yb) of the colorimetric value according to the Munsell Color System of the colored light of the cured product on a black background and the Y value (Yw) of the colorimetric value according to the Munsell Color System of the colored light of the cured product on a white background are each measured using a color difference meter, the ratio therebetween, Yb/Yw, being within a range of 0.2 to 0.5.

US Pat. No. 11,066,478

INTRAVESICAL THERAPY FOR BLADDER CANCER

PHOTOCURE ASA, Oslo (NO)...


1. A method of therapy for bladder cancer in a bladder cancer patient comprising the instillation into the bladder of said patient of a composition comprising anti-PD-L1 antibodies and/or anti-PD-1 antibodies, wherein the composition further comprises hexyl 5-ALA ester or a pharmaceutically acceptable salt thereof and wherein after instillation of said composition into the bladder of said patient the inside of said bladder is exposed to light.
US Pat. No. 11,064,670

SOYBEAN CULTIVAR CS1661278

Syngenta Crop Protection ...


1. A plant, a plant part, or a seed of soybean variety CS1661278, wherein a representative sample of seed of said soybean variety CS1661278 has been deposited under ATCC Accession Number PTA-126987.
US Pat. No. 11,065,184

OIL-IN-WATER EMULSION FOR MAKING UP AND CARING FOR THE LIPS

LVMH RECHERCHE, Saint Je...


1. A liquid product for making up and caring for the lips as an oil-in-water emulsion comprising:from 25% by weight to 45% by weight of a mixture of water and of at least one polyol,
from 35% by weight to 60% by weight of a mixture of oils, each having a refractive index, measured at a temperature ranging from 20° C. to 25° C., which is greater than or equal to 1.460,
from 0.01% by weight to 20% by weight of a coloring material,
the percentages being expressed with respect to the weight of the product,
wherein the liquid product comprises a first polyethylene glycol ether of stearyl alcohol comprising from 2 to 5 oxyethylene units, a second polyethylene glycol ether of stearyl alcohol comprising from 15 to 25 oxyethylene units, and an acrylamido-2-methylpropane sulfonate copolymer.

US Pat. No. 11,066,479

MONOCLONAL ANTIBODIES TARGETING GLYPICAN-2 (GPC2) AND USE THEREOF

The United States of Amer...


1. An isolated variable heavy (VH) single domain monoclonal antibody that binds glypican-2 (GPC2), comprising a complemetarity determining region 1 (CDR1), a CDR2 and a CDR3, wherein the VH single domain monoclonal antibody comprises:the CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 2;
the CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 4;
the CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 6;
the CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 8;
the CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 10; or
the CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 12.

US Pat. No. 11,064,671

SOYBEAN CULTIVAR CE1661319

Syngenta Crop Protection ...


1. A plant, a plant part, or a seed of soybean variety CE1661319, wherein a representative sample of seed of said soybean variety CE1661319 has been deposited under ATCC Accession Number PTA-126988.
US Pat. No. 11,065,185

HAIR COLORING METHOD

SUNNYPLACE CO., LTD., Ta...


1. A hair coloring method comprising:a step of applying a mixture of the following (A) and (B) in a predetermined ratio:(A) a hair coloring agent comprising at least a basic dye, an HC dye, a second amino acid, a first cationic surfactant, a thickener, an oil agent, a first pH adjuster, and a wetting agent, wherein the hair coloring agent has a pH of 6.8 or more; and
(B) a hair cosmetic comprising at least an alkaline agent, a first amino acid, a higher alcohol having 12 to 22 carbon atoms, a surfactant, and a thickener, wherein the hair cosmetic has a pH from 7.0 to 11.5;

a step of providing a predetermined time after applying the mixture; and
a step of applying a cuticle care agent after the predetermined time.

US Pat. No. 11,066,480

ANTI-MUC16 ANTIBODIES AND USES THEREOF

MEMORIAL SLOAN KETTERING ...


1. An antibody or antigen-binding fragment thereof that immunospecifically binds to MUC16, wherein the antibody or antigen-binding fragment thereof comprises:(a) (i) a VH comprising a VH CDR1 comprising the amino acid sequence TX1GMGVG (SEQ ID NO:103), wherein X1 is L or V; a VH CDR2 comprising the amino acid sequence HIWWDDX2DKYYX3PALKS (SEQ ID NO:104), wherein X2 is E or absent, and X3 is Y or N; and a VH CDR3 comprising the amino acid sequence IGTAQATDALDY (SEQ ID NO:105); and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence RSSKSLX4X5SNGNTYLY (SEQ ID NO:106), wherein X4 is R or L, and X5 is K or H; a VL CDR2 comprising the amino acid sequence YMSNLAS (SEQ ID NO:107); and a VL CDR3 comprising the amino acid sequence MQX6LEX7PLT (SEQ ID NO:108), wherein X6 is G or S, and X7 is H or Y; or
(b) (i) a VH comprising a VH CDR1 comprising the amino acid sequence GFSLX8TX9GM (SEQ ID NO:109), wherein X8 is N or S, and wherein X9 is L or V; a VH CDR2 comprising the amino acid sequence WDDX10 (SEQ ID NO:110), wherein X10 is E or absent; and a VH CDR3 comprising the amino acid sequence GTAQATDALD (SEQ ID NO:111); and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence SKSLX11X12SNGNTY (SEQ ID NO:112), wherein X11 is L or R, and X12 is H or K; a VL CDR2 comprising the amino acid sequence YMS (SEQ ID NO:113); and a VL CDR3 comprising the amino acid sequence X13LEX14PL (SEQ ID NO:114), wherein X13 is G or S, and X14 is H or Y; or
(c) (i) a VH CDR1 comprising the amino acid sequence GFSLX15TX16GMG (SEQ ID NO:115), wherein X15 is N or S, and X16 is V or L; a VH CDR2 comprising the amino acid sequence IWWDDX17DK (SEQ ID NO:116), wherein X17 is E or absent; and a VH CDR3 comprising the amino acid sequence X18RIGTAQATDALDY (SEQ ID NO:117), wherein X18 is T, A, or S; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence KSLX19X20SNGNTY (SEQ ID NO:118), wherein X19 is V or L, and X20 is H or K; a VL CDR2 comprising the amino acid sequence YMS (SEQ ID NO:119); and a VL CDR3 comprising the amino acid sequence MQSLEYPLT (SEQ ID NO:120); or
(d) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:83, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:84, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:85; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:86, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:87, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:88; or
(e) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:89, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:90, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:91; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:92, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:93, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:94; or
(f) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:95, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:96, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:97 and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:98, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:99, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:100; or
(g) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:23, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:24, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:25; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:26, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:27, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:28; or
(h) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:29, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:30, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:31; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:32, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:33, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:34; or
(i) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:35, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:36, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:37; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:38, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:39, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:40; or
(j) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:43, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:44, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:45; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:46, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:47, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:48; or
(k) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:49, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:50, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:51; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:52, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:53, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:54; or
(l) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:55, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:56, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:57; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:58, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:59, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:60; or
(m) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:3, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:4, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:5; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:6, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:7, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:8; or
(n) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:9, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:10, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:11; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:12, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:13, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:14; or
(o) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:15, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:16, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:17; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:18, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:19, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:20; or
(p) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:63, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:64, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:65; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:66, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:67, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:68; or
(q) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:69, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:70, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:71; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:72, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:73, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:74; or
(r) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:75, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:76, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:77; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:78, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:79, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:80.

US Pat. No. 11,067,508

ENZYME TRANSDUCERS AND SENSORS BASED ON DNA LOOPS

The Government of the Uni...


1. An enzyme sensor system comprising:a loop transducer comprising a stiffening domain of about 30 to 55 base pairs in length, a cleavage domain cleavable by an enzyme of interest, and a first hybridizing domain of about 12 to 27 base pairs in length; and
an output gate comprising a second hybridizing domain of about 8 to 15 base pairs in length and complementary to the first hybridizing domain, a fluorophore, and a quencher,
wherein the system is configured so that in the absence of the first hybridizing domain, the quencher quenches the fluorophore, and upon hybridization of the two domains, the quencher become separated from the fluorophore sufficiently to allow fluorescence thereof.

US Pat. No. 11,064,672

COTTON VARIETY 18R438B3XF

Monsanto Technology LLC, ...


1. A plant of cotton variety 18R438B3XF, wherein representative seed of said variety have been deposited under ATCC Bigelow Accession No. 202010018.
US Pat. No. 11,065,186

ORAL CARE COMPOSITIONS

Colgate-Palmolive Company...


1. An oral care composition comprising an aqueous soluble tin phosphate complex formed from a mixture comprising tin (II) fluoride or tin (II) chloride and a tripolyphosphate salt;wherein the complex is formed in situ in an aqueous solution and combined with the composition;
or is isolated from the aqueous solution in solid form and combined with the composition;
or is lyophilized and combined with the composition;
or is isolated with an anti-solvent and combined with the composition,
and the complex is formed from tin (II) fluoride or tin (II) chloride and the tripolyphosphate salt in a molar ratio of 2P:1Sn to 10P:1Sn, and
wherein the complex is present in an amount of 2 to 30 weight % by weight of the composition,
wherein the composition is in the form of a mouthwash, oral gel, or dentifrice.

US Pat. No. 11,066,481

ANTIBODIES TO COAGULATION FACTOR XIA AND USES THEREOF

The Regents of the Univer...


1. An isolated monoclonal antibody, or an antigen-binding portion thereof, that specifically binds the Factor XIa catalytic domain, wherein the antibody or antigen-binding portion comprises HCDR1-3 and LCDR1-3 comprising the amino acid sequences of:a) SEQ ID NOs: 2, 3, 4, 8, 9, and 10, respectively; or
b) SEQ ID NOs: 5, 6, 4, 11, 12, and 13, respectively.

US Pat. No. 11,064,673

ENDOPHYTIC MICROBIAL SYMBIONTS IN PLANT PRENATAL CARE

University of Saskatchewa...


1. A plant seed manually or mechanically coated with at least one endophyte, wherein the plant is a cereal that is not wheat and the endophyte is a Streptomyces sp. strain or culture thereof which is deposited under IDAC 081111-06 or which comprises the 16S rDNA sequence as shown in SEQ ID NO:6.
US Pat. No. 11,065,187

PARTICLE BOUND PHOTOSENSITIZER MOLECULE WITH REDUCED TOXICITY

International Business Ma...


1. A lotion comprising:an active ingredient of a photosensitizer derivative compound selected from the group consisting of octocrylene, octinoxate, homosalate, octisalate, and combinations thereof, wherein the photosensitizer derivative compound is bound to a metal oxide-containing particle through a tetherable structure selected from the group consisting of reacted epichlorohydrin, protected ethylene ether, terminal hydroxyl-alkyne-functionalized alkyl chain, alkyl-2-cyanate, alkyl-2-cyanoate, alkyl acetate and combinations thereof, the compound size of the photosensitizer derivative compound that is bound to the oxide-containing particle is on a microscale having a diameter of up to 100 microns; and
a lotion liquid base containing the active ingredient mixed therein.

US Pat. No. 11,066,482

SPECIFIC PLASMIN INACTIVATION BY ANTICATALYTIC ANTIBODY


1. A method of inhibiting plasmin activity in a subject in need thereof comprising administering to the subject an effective amount of a plasmin inhibiting composition comprising a plasmin protease domain-specific binding monoclonal antibody or functional fragment thereof that inhibits fibrinolysis, wherein the monoclonal antibody or functional fragment thereof comprises variable region light chain CDR amino acid sequences CDR1, CDR2 and CDR3 defined by SEQ ID NOS:9-11 and variable region heavy chain CDR amino acid sequences CDR1, CDR2 and CDR3 defined by SEQ ID NOS:12-14.
US Pat. No. 11,069,828

METHOD FOR MANUFACTURING PHOTOELECTRIC CONVERSION DEVICE

KANEKA CORPORATION, Osak...


1. A method for manufacturing a crystalline silicon-based solar cell, the method comprising:performing a plasma treatment on a plurality of conductive single-crystalline silicon substrates in a chemical vapor deposition (CVD) chamber, each of the conductive single-crystalline silicon substrates having an intrinsic silicon-based layer on a first principal surface thereof,
wherein the first principal surface of the conductive single-crystalline silicon substrates has a pyramidal texture comprising a plurality of projections, each having a top portion, a middle portion, and a valley portion,
wherein the plasma treatment comprises introducing a hydrogen gas and a silicon containing gas into the CVD chamber and exposing a surface of the intrinsic silicon-based layer to hydrogen plasma,
wherein an amount of the hydrogen gas introduced into the CVD chamber during the plasma treatment is 150 to 2500 times an amount of the silicon-containing gas introduced into the CVD chamber wherein the plasma treatment forms a first thin-film on the intrinsic silicon-based layer at least at the valley portion,
wherein the crystalline silicon-based solar cell comprises:the conductive single-crystalline silicon substrate;
an intrinsic silicon-based thin-film comprising the silicon-based layer and the first thin-film; and
a conductive silicon-based thin-film,

wherein the intrinsic silicon-based thin-film and the conductive silicon-based thin-film are disposed in this order on the first principal surface of the conductive single-crystalline silicon substrate, and
wherein forming the intrinsic silicon-based layer is performed on the first principal surface of the conductive single-crystalline silicon substrate by plasma-enhanced CVD with a silicon containing gas and a hydrogen gas introduced into a CVD chamber, and an amount of the hydrogen gas introduced into the CVD chamber during the formation of the intrinsic silicon-based layer is less than 50 times an amount of the silicon containing gas introduced into the CVD chamber.

US Pat. No. 11,066,483

CYTOTOXICITY-INDUCING THERAPEUTIC AGENT

Chugai Seiyaku Kabushiki ...


1. A bispecific antibody that comprises:a first light chain comprising a first VL domain and a first CL domain;
a second light chain comprising a second VL domain and a second CL domain;
a first heavy chain comprising a first heavy chain variable region and a first heavy chain constant region, wherein the first heavy chain constant region is a non-wild-type heavy chain constant region comprising the sequence of one of SEQ ID NOs: 23, 24, 25 and 26, with one or more amino acid substitutions and optionally a deletion of the amino acids at EU numbering positions 446 and 447; and
a second heavy chain comprising a second heavy chain variable region and a second heavy chain constant region, wherein the second heavy chain constant region is a non-wild-type heavy chain constant region comprising the sequence of one of SEQ ID NOs: 23, 24, 25 and 26, with one or more amino acid substitutions and optionally a deletion of the amino acids at EU numbering positions 446 and 447, wherein the amino acid sequence of the second heavy chain constant region is the same as or different from the amino acid sequence of the first heavy chain constant region, and is of the same isotype as the first heavy chain constant region;
wherein the first light chain and the first heavy chain associate to form a first antigen- binding domain that binds to CD3,
wherein the second light chain and the second heavy chain associate to form a second antigen-binding domain that does not bind to CD3, and that does bind to a cancer antigen that is not CD3,
wherein the first heavy chain constant region associates with the second heavy chain constant region,
wherein, when assessed by a surface plasmon resonance technique, the ability of the associated first and second heavy chain constant regions to bind to a given human Fc? receptor is reduced, compared to the ability of a wild-type human IgG antibody of the same isotype as the bispecific antibody to bind to the human Fc? receptor, as a result of at least one of the one or more amino acid substitutions within the first and second heavy chain constant regions,
wherein the at least one substitution in the first and second heavy chain constant regions represents a change in amino acid sequence compared to the amino acid sequence of the heavy chain constant regions of the wild-type human IgG antibody, and
wherein at least one of the amino acid substitutions that result in the reduced ability to bind to the human Fc? receptor is at a position selected from the following EU numbering positions in each of the first and second heavy chain constant regions: 220, 226, 229, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 264, 265, 266, 267, 269, 270, 295, 296, 297, 298, 299, 300, 325, 327, 328, 329, 330, 331, and 332.

US Pat. No. 11,065,189

LIQUID PERSONAL CLEANSING COMPOSITION

Conopco, Inc., Englewood...


1. A liquid personal cleansing composition comprising:a. 0.1 to 20% by wt. of individual surfactants or mixtures of C10, C12 and C14 acyl glycinates;
b. 2.0 to 20% by wt. of C14 acyl glutamate;
c. 1 to 25% by wt. of C8 to C24 fatty acid soap,
in combination with other anionic, non-ionic or amphoteric/zwitterionic surfactants or mixtures thereof.

US Pat. No. 11,066,484

CELLULOSE ACETATE AND METHOD FOR PRODUCING CELLULOSE ACETATE

DAICEL CORPORATION, Osak...


1. A cellulose acetate, wherein:a total content of calcium and magnesium is 2.8 to 3.5 ?mol/g;
a 6 percent viscosity is 40 to 80 mPa·s;
a degree of filtration Kw is 35 g?1 or less;
a molecular weight distribution Mw/Mn is 3.00 or less; and
a degree of acetylation is 61.3 to 62.3%.

US Pat. No. 11,069,054

SYSTEM AND METHOD FOR AUTOMATED DETECTION AND MONITORING OF DYSPLASIA AND ADMINISTRATION OF IMMUNOTHERAPY AND CHEMOTHERAPY

VisionGate, Inc., Phoeni...


1. A method of training and using an automated dysplastic cell algorithmic classifier directed to treating a malignancy in a subject comprising:a) obtaining a set of known unique dysplastic cells indicating an abnormal lung process and a plurality of known normal cells;
b) operating an optical tomography system to generate a first set of 3D images of the set of known unique dysplastic cells indicating an abnormal lung process and a second set of 3D images for the plurality of known normal cells;
c) computing a plurality of dysplastic cell feature measurements from the first set of 3D images;
d) computing a plurality of normal cell feature measurements from the second set of 3D images;
e) operating a training algorithm using the plurality of dysplastic cell feature measurements and the normal cell feature measurements to classify the set of known unique dysplastic cells and plurality of known normal cells into classified dysplastic cell types and classified normal cell types;
f) comparing the classified dysplastic cell types and classified normal cell types with diagnostic truth to determine an accuracy value;
g) comparing the accuracy value to a predetermined performance bound;
h) if the accuracy value does not fall within the predetermined performance bound, then adjusting dysplastic cell feature values for each of the plurality of dysplastic cell feature measurements and adjusting normal cell feature values for each of the plurality of normal cell feature measurements according to the training algorithm;
i) repeating steps e) through h) until the accuracy value falls within the predetermined performance bound and providing the last adjusted dysplastic cell feature values for each of the plurality of dysplastic cell feature measurements as trained dysplastic cell feature measurements and providing the last adjusted normal cell feature values for each of the plurality of normal cell feature measurements as trained normal cell feature measurements;
j) inputting the trained dysplastic cell feature measurements and trained normal cell feature measurements into a dysplastic classifier;
k) operating the optical tomography system to generate a third set of 3D patient images of cells based on pseudo-projections obtained from a patient specimen derived from spontaneous cough sputum;
l) operating the dysplastic cell classifier to determine whether cells represented by the third set of 3D patient images comprise dysplastic cell types; and
m) when cells represented by the third set of 3D patient images are classified as dysplastic cell types, then administering an immunomodulating agent to the subject over a predetermined time period.

US Pat. No. 11,066,485

MODIFIED STARCH

Corn Products Development...


1. An octenyl succinic acid (OSA) modified starch comprising a starch molecule degraded by at least one enzyme capable of cleaving the 1,4-linkages of the starch molecule from the non-reducing ends to produce short chain saccharides, wherein a content of non-covalently bound, free octenyl succinic acid in the OSA modified starch is less than about 0.50% by weight, based on the total weight of the OSA modified starch and wherein a content of an alpha-1,6-glycosidic linkages is higher than 12% in the OSA modified starch based on the total weight of the OSA modified starch.
US Pat. No. 11,065,191

METHOD FOR THICKENING A COSMETIC FORMULATION USING AN ALKALI SWELLABLE EMULSION OF A POLYMER WITH AMPS AND WHICH IS RICH IN ACRYLIC ACID

COATEX, Genay (FR)


1. A method for thickening a formulation, the method comprising:contacting the formulation with a direct aqueous emulsion of a polymer, followed by
regulating a pH of the formulation to a value between 5 and 7, thereby forming a thickened formulation,
wherein the emulsion is free from surfactants and organic solvents other than water and
the polymer consists, expressed as a content by weight of monomers therein, of:a) from 20% to 60% by weight of acrylic acid and, optionally, methacrylic acid, wherein a content by weight of acrylic acid compared to a total weight of acrylic and methacrylic acid is at least 50%,
b) from 40% to 80% by weight of ethyl acrylate, butyl acrylate, methyl methacrylate, or any combination thereof,
c) from 0.05% to 22% by weight of 2-acrylamido-2-methylpropane sulfonic acid, and
d) from 0 to 1% by weight of at least one cross-linked monomer.


US Pat. No. 11,065,192

MASCARA COMPOSITIONS INCLUDING VINYLPYRROLIDONE HOMOPOLYMER AND AN ACRYLIC FILM-FORMING POLYMER


1. A mascara composition consisting essentially of:a vehicle comprising water;
a film-forming polymer portion consisting of a high molecular weight vinylpyrrolidone homopolymer, and an acrylic polymer having a glass transition temperature of 65° C. or more,
wherein the high molecular weight vinylpyrrolidone homopolymer is present in a concentration of at least 10 percent by weight of the mascara composition,
wherein the film-forming portion is stabilized in the vehicle,
wherein the mascara composition is substantially free of wax, substantially free of oil, and substantially free of glycols, and
wherein the mascara composition is self-curling as to induce curling of eyelashes upon drying with the use of an applicator for curling eyelashes.

US Pat. No. 11,065,193

COMPOSITIONS AND TREATMENTS FOR KERATINOUS MATERIALS PROVIDING DAMAGE PROTECTION AND SENSORIAL BENEFITS


1. A hair treatment composition comprising:an antioxidant component consisting of:at least one polyphenol selected from the group consisting of baicalin, pine bark extract, polydatin, and ellagic acid; and
optionally, sodium silicate; and

a color altering system comprising:a bleach composition comprising at least one oxidant; and
a developer,

wherein the color altering system does not include a colorant selected from oxidative dye precursors, and
wherein the antioxidant component is present in an amount selected to confer protection to keratinous material from damaging effects of the bleach composition when the treatment composition is applied to keratinous material and thereby enhance and protect one or more sensorial features, and preserve the mechanical properties and native amino acid structure of the keratinous material.

US Pat. No. 11,065,194

COSMETIC USE OF EXTRACTS OF SALVIA MILTIORRHIZA ROOTS, SPECIAL EXTRACTS OF SALVIA MILTIORRHIZA ROOTS AND COSMETIC COMPOSITIONS CONTAINING SUCH EXTRACTS


1. A method of treating sensitive skin, the method consisting of the step of: applying topically to the sensitive skin an effective amount of an extract of Salvia miltiorrhiza roots, wherein the extract is obtained by extracting Salvia miltiorrhiza roots with a water/butylene glycol mixture and wherein the extract does not contain molecules with a molecular mass exceeding 2000 Da.
US Pat. No. 11,066,490

CYANOETHYL GROUP-CONTAINING POLYMER AND PREPARATION METHOD THEREOF

LG Chem, Ltd.


1. A method of preparing a cyanoethyl group-containing polymer, the method comprising mixing a reactive functional group-containing polymer, a cyanoethyl group-introducing precursor, a basic catalyst, and a first solvent to prepare a mixture, and during a cyanoethylation of the mixture, adding a second solvent so that Ra calculated by the following Equation 1 is less than 6:(Ra)2=4(?D2??D1)2+(?P2??P1)2+(?H2??H1)2??[Equation 1]
in Equation 1, ?D2, ?P2, and ?H2 represent a solubility parameter due to a dispersion force, a solubility parameter due to a dipolar intermolecular force, and a solubility parameter due to hydrogen bonding of a mixture obtained by mixing the reactive functional group-containing polymer and the cyanoethyl group-introducing precursor at a molar ratio of 100-x:x, respectively, and x represents a ratio of replacement by a cyanoethyl groups, which is measured at any one point, and
?D1, ?P1, and ?H1 represent a solubility parameter due to a dispersion force, a solubility parameter due to a dipolar intermolecular force, and a solubility parameter due to hydrogen bonding of a solvent system which is used in the cyanoethylation at any one point, respectively,
wherein the cyanoethyl group-containing polymer comprises 1.0% or less of a repeating unit including —OCH2CH2CONH2 and ions thereof and 2.0% or less of a repeating unit including —OCH2CH2COOH and ions thereof, with respect to total repeating units included in the cyanoethyl group-containing polymer.

US Pat. No. 11,065,197

SOLUBLE ESTRADIOL CAPSULE FOR VAGINAL INSERTION

TherapeuticsMD, Inc., Bo...


1. A soft gelatin vaginal insert containing a fill material having a viscosity between 50 and 380 cP as measured at 25° C., the fill material comprising one or more C6 to C14 fatty acid mono-, di-, or triesters of glycerol, a nonionic surfactant comprising PEG-6 stearate, PEG-32 sterate, and ethylene glycol palmitostearate, and 1 to 10 mcg of estradiol,wherein estradiol is the only active ingredient in the vaginal insert;
further wherein the insert is made by a process comprising:
a) making a pre-fill material consisting essentially of:i. one or more C6 to C14 fatty acid mono-, di-, or triesters of glycerol;
ii. a nonionic surfactant consisting essentially of PEG-6 stearate, PEG-32 stearate, and ethylene glycol palmitostearate; and
iii. 1 to 10 mcg of estradiol;

b) forming a soft gelatin capsule, and
c) filling the soft gelatin capsule with the pre-fill material to make the insert.

US Pat. No. 11,066,492

PROCESS FOR MANUFACTURING ETHYLENE POLYMERS AND USING MODIFIERS

ExxonMobil Chemical Paten...


1. A process for producing an ethylene polymer comprising:compressing ethylene monomer in at least a first compressor and a second compressor to a pressure of 1000 to 3000 bar to produce a compressed ethylene monomer;
introducing a blend comprising an initiator and a first portion of a modifier, optionally in combination with one or more solvents, into a discharge section of a second stage of the second compressor;
introducing a second portion of the modifier into a suction section of the second stage of the second compressor such that the second portion of the modifier bypasses a first stage of the second compressor;
introducing a mixture of the compressed ethylene monomer and the blend into a reactor in at least one location of the reactor, where the ethylene monomer polymerizes forming a reaction mixture comprising unreacted ethylene monomer and the ethylene polymer; and
separating the ethylene polymer from the reaction mixture.

US Pat. No. 11,066,749

CORROSION INHIBITION OF HCL TREATMENT FLUIDS WITH ENVIRONMENTALLY COMPATIBLE SOLVENT

Halliburton Energy Servic...


1. A corrosion inhibitor composition comprising:an organic solvent comprising tetrahydrofurfuryl alcohol;
a nitrogen containing compound, wherein the nitrogen containing compound includes at least one of:the product of a reaction between at least one aldehyde and at least one amide that is not formamide or a formamide derivative;
a quaternary nitrogen containing compound; and
combinations thereof, and

an aqueous acid solution comprising HCl.

US Pat. No. 11,064,684

MULTIPLEXED GENOME EDITING

President and Fellows of ...


1. A genetically engineered porcine cell in which at least 97% of the porcine endogenous retrovirus (“PERV”) pol genes comprise a genetically engineered genomic indel.
US Pat. No. 11,064,940

METHODS FOR DETECTING AND TREATING PAIN USING BRAIN ACTIVITY

Rhode Island Hospital, P...


1. A method for detecting pain in a subject, the method comprising:(a) recording theta or gamma waveforms in a somatosensory cortex or a frontal cortex of the subject by electroencephalography (EEG);
(b) applying fast Fourier transfer (FFT) to convert the waveforms from the time domain to the frequency domain, thereby producing power spectral density (PSD); and
(c) determining power amplitude from the PSD, wherein an increase in the power amplitude in a theta or gamma frequency band in the somatosensory cortex or the frontal cortex relative to baseline serves as an indicator of pain.

US Pat. No. 11,065,198

DISPERSIBLE COMPOSITIONS

Janssen Sciences Ireland ...


1. A composition having a granular fraction and an extragranular fraction, wherein the fractions comprise the following ingredients by weight based on the total weight of the composition:Granular Fraction
2.75 mg of rilpivirine HCl;
1% to 8% of a diluent;
0.01 to 2.5% of a wetting agent;
0 to 10% of a binder; and
0.1% to 5% of a disintegrant; and
Extragranular Fraction
35% to 87% of microcrystalline cellulose;
1% to 5% of a disintegrant;
0.01 to 2.5% of a wetting agent; and
0 to 5% of a lubricant.

US Pat. No. 11,066,750

METAL CORROSION INHIBITION

Momentive Performance Mat...


6. A corrosion-inhibited metal selected from the group consisting of brass, bronze, iron, steel, copper and aluminum having at least a portion of its exposed surface in contact with a static or flowing liquid aqueous medium, the liquid aqueous medium consisting of:(I) a water containing liquid, consisting of at least 20 weight percent water based on the weight of the water containing liquid, selected from the group consisting of an aqueous refrigerating solution, an acidified pickling solution, river water containing chlorides, carbonates and sulfates, corrosive well water, or a solution of water with water soluble liquid polyhydric alcohol, water soluble liquid hydroxyl end-blocked polyalkylene oxide, water soluble liquid alkoxy end-blocked polyalkylene oxide, water soluble liquid organic sulfoxide, water soluble liquid formamide and water soluble liquid cyclic ether free of olefinic unsaturation; and
(II) a ureido silane metal corrosion inhibiting amount, ranging from 1.1 to 5.1 weight percent based on the weight of the liquid aqueous medium, of at least one ureido silane selected from the group consisting of gamma-ureidopropyltrimethoxysilane, gamma-ureidopropyltriethoxysilane, gamma-ureidopropyldimethoxyethoxysilane, gamma-ureidopropylmethoxydiethoxysilane, their hydrolyzates, their partial and/or substantially complete condensates and combinations of any of the foregoing; and
wherein the at least one ureido silane is uniformly dissolved in the liquid aqueous medium, and wherein the pH of the liquid aqueous medium is adjusted to a value of from 3 to 5 to inhibit the formation of a gel precipitate for a period for from 2 hours to 30 days and corrosion inhibition is provided for a period of from 2 hours to 30 days.

US Pat. No. 11,064,685

NON-HUMAN ANIMAL MODELS OF RETINOSCHISIS

REGENERON PHARMACEUTICALS...


1. A genetically modified rodent whose genome comprises a mutation in exon 3 or exon 5 of an endogenous rodent Rs1 gene, wherein the mutation in exon 3 or exon 5 encodes a C59S or R141C amino acid substitution in the endogenous rodent Rs1 polypeptide, respectively;wherein the rodent is a mouse or rat; and
wherein the rodent expresses the rodent Rs1 gene comprising the mutation, and displays one or more symptoms of Retinoschisis when the rodent is a female rodent homozygous for the rodent Rs1 gene comprising the mutation, or when the rodent is a male rodent hemizygous for the rodent Rs1 gene comprising the mutation.

US Pat. No. 11,065,199

DEVICES AND METHODS FOR TREATING EAR PAIN

Try This First, Inc., Wa...


1. An apparatus for promoting drainage of fluid from a Eustachian tube of a user, comprising:a handle; and
a dissolvable composition attached to the handle, the dissolvable composition comprising:a first surface that is substantially flat and parallel to the handle;
a second surface that is substantially convex and configured to fit within an oral cavity of the user and to contact a roof of the oral cavity of the user;
one or more of:isomalt;
citric acid;
xylitol;
vitamin C; or
lemon oil,


wherein, the dissolvable composition attached to the handle is configured to promote drainage of the fluid from the Eustachian tube of the user via a negative pressure formed within the oral cavity of the user.

US Pat. No. 11,065,200

MUCOADHESIVE DEVICES FOR THE RELEASE OF PROBIOTICS AND FOR THE MAINTENANCE OF THEIR ENZYME ACTIVITIES

MENDES S.R.L., Ardea (IT...


1. A method for the preparation of a bi-layered, stable, dehydrated mucoadhesive film having a surface layer of dehydrated lactic acid bacteria or bifidobacteria, or an enzyme derived from said lactic bacteria or bifidobacteria, or mixtures thereof,the method comprising:
(a) Mixing a mucoadhesive polymer with water and a plasticizing substance in a quantity from between about 0% to 5% w/w based on the weight of the mucoadhesive polymer, thereby making a mixture;
(b) Pouring the mixture onto a surface to form a substantially uniform thickness and drying at a temperature of about greater than or equal to about 30° C., thereby generating a dehydrated mucoadhesive film having a surface,
(c) depositing and distributing an aliquot of the lactic acid bacteria or bifidobacteria bacteria, or the enzyme derived from said lactic bacteria or bifidobacteria, or mixtures thereof, in dehydrated form onto the dehydrated mucoadhesive film surface, thereby generating a bi-layered dehydrated mucoadhesive film comprising a surface layer of dehydrated lactic acid bacteria or bifidobacteria bacteria, or the enzyme derived from said lactic bacteria or bifidobacteria or mixtures thereof; and
(d) drying the mucoadhesive film surface until the bi-layered dehydrated mucoadhesive film reaches a constant weight, thereby producing a stable, dehydrated bi-layered mucoadhesive film.

US Pat. No. 11,066,496

SUPER ABSORBENT POLYMER AND METHOD FOR PREPARING SAME

LG Chem, Ltd.


1. A method for preparing a super absorbent polymer comprising:thermally polymerizing or photo-polymerizing a monomer composition including an acrylic acid-based monomer having an acidic group, of which at least a part is neutralized, and a polymerization initiator to form a hydrogel polymer;
drying the hydrogel polymer;
pulverizing the dried polymer;
mixing the pulverized polymer with a surface crosslinking agent and an aliphatic alcohol of C6 to C20;
heating the polymer obtained by mixing the surface crosslinking agent and the aliphatic alcohol of C6 to C20 to a temperature of 160 to 200° C. to carry out a surface modification.

US Pat. No. 11,066,753

PLATED POLYMERIC ARTICLE INCLUDING TIN/COPPER TIE/SEED LAYER

3M Innovative Properties ...


1. A plated article comprisinga) a polymeric substrate bearing
b) a tie/seed layer in direct contact with the polymeric substrate and
c) a plated metal layer,wherein the tie/seed layer has a thickness of less than 0.95 ?m,
wherein the tie/seed layer comprises two or more layers of tin alternating with two or more layers of copper,
wherein the layers of tin comprising the tie/seed layer are sputter coated layers and the layers of copper comprising the tie/seed layer are sputter coated layers and wherein the plated metal layer comprises copper and tin in an atomic ratio of greater than 65:35.


US Pat. No. 11,066,497

LIQUID FORMULATION FOR REACTION INJECTION MOLDING AND MANUFACTURING METHOD THEREOF

RIMTEC CORPORATION, Toky...


1. A method for manufacturing a liquid formulation for reaction injection molding for polymerizing a norbornene-based monomer in the presence of a metathesis polymerization catalyst comprising tungsten as a center metal, the liquid formulation comprising a norbornene-based monomer, provided that in case where the norbornene-based monomer includes exo-dicyclopentadiene, a content of exo-dicyclopentadiene is from 0 to 2% by mass of the norbornene-based monomer, an activator of the catalyst, and an ether compound wherein the ether compound is dipropyleneglycol dimethyl ether,the method comprising the step of mixing a liquid mixture comprising the ether compound and the activator of the catalyst with the norbornene-based monomer,
wherein the norbornene-based monomer is selected from the group consisting essentially of norbornene, norbornenes having an alkyl group, norbornenes having an alkenyl group, norbornenes having an aromatic ring, norbornenes having a polar group including an oxygen atom, dicyclopentadiene, methyldicyclopentadiene, tricyclo[5.2.1.02,6]deca-8-ene, tetracyclo[9.2.1.02,10.03,8]tetradeca-3,5,7,12-tetraene, tetracyclo[10.2.1.02,11.04,9] pentadeca-4,6,8,13-tetraene, tricyclopentadiene, tetracyclododecene, tetracyclododecenes having an aromatic ring, tetracyclododecenes having a substituent including an oxygen atom, tetracyclododecenes having a substituent including a halogen atom, tetracyclododecenes having a substituent including a silicon atom, hexacycloheptadecene, hexacycloheptadecenes having an alkyl group, hexacycloheptadecenes having a double bond outside the ring, hexacycloheptadecenes having an aromatic ring, hexacycloheptadecenes having a substituent including an oxygen atom, hexacycloheptadecenes having a substituent including a halogen atom, and hexacycloheptadecenes having a substituent including a silicon atom.

US Pat. No. 11,065,203

LIPOSOMAL COMPOSITIONS AND USES OF SAME


19. A composition-of matter comprising a hybrid liposome composed of a whole cell membrane fraction of a cell, wherein said liposome exhibits native membrane symmetry and expression of native markers and wherein said liposome is devoid of the cytoplasmic content of said cell and wherein said hybrid liposome is fused to another liposome.
US Pat. No. 11,066,499

MEDIUM DENSITY POLYETHYLENE COMPOSITIONS

Chevron Phillips Chemical...


1. An ethylene alpha-olefin copolymer having:(a) a density of from about 0.910 g/cc to about 0.940 g/cc;
(b) a weight average molecular weight of from about 150,000 g/mol to about 300,000 g/mol;
(c) a CY-a value of from about 0.35 to about 0.65;
(d) a ratio of high load melt index (HLMI) to melt index (MI) of from about 100 to about 2500, wherein the copolymer has an HLMI of from about 4 dg/min to about 25 dg/min when tested in accordance with ASTM D1238 under a force of 21.6 kg at 190° C., and wherein the MI is measured in accordance with ASTM D1238 under a force of 2.16 kg at 190° C.;
(e) a 1% secant modulus in the machine direction of from 90,000 psi to about 116,000 psi when tested in accordance with ASTM D882; and
(f) a molecular weight distribution of from about 4 to less than about 40.

US Pat. No. 11,065,205

IMMEDIATE/DELAYED DRUG DELIVERY

DRUG DELIVERY INTERNATION...


1. A press-coated tablet formulation for an immediate, followed by a delayed release of an active agent, the tablet comprising:(a) a core comprising an active agent together with an excipient(s); and
(b) a delayed release layer surrounding the core and comprising a wax and a low substituted hydroxypropyl cellulose in a ratio of 40:60 to 60:40 w/w; wherein the delayed release layer substantially delays release of the active agent within the core for between 3-8 hours after administration of the tablet to a subject and thereafter a pulsed release of the active agent from the core occurs, such that at least 70% of the active agent in the core is released within 5-45 minutes and wherein the low substituted hydroxypropyl cellulose is micronized with a mean particle diameter of 20 ?m and has a molecular weight of 115,000 and a hydroxypropyl cellulose content of 8%; and
(c) a top-coating layer comprising a portion of an active agent together with one or more excipients wherein a substantially immediate pulsed release of the active agent occurs following administration to the subject of the tablet.

US Pat. No. 11,065,206

TOPICAL FORMULATIONS INCLUDING LIPID MICROCAPSULE DELIVERY VEHICLES AND THEIR USES

Avidas Pharmaceuticals, L...


1. A topical formulation, comprising: (a) tocopherol, tocotrienol, or mixtures thereof present in an amount of 0%< to 20% based on the total weight of said topical formulation; (b) a stabilizer/surfactant component present in an amount of 1%< to 20% based on the total weight of said topical formulation; (c) an aqueous component present in an amount of 35%< to 99% based on the total weight of said topical formulation; and (d) one or more transdermal active agents,wherein said tocopherol, tocotrienol, or mixtures thereof, said stabilizer/surfactant component, and said one or more transdermal active agents are mixed to produce a mixture; and said aqueous component is added to said mixture to form a lipid microcapsule within said topical formulation, wherein at least part of said aqueous component is present in said topical formulation outside of said lipid microcapsule;
wherein said lipid microcapsule is free of a dicetyl phosphate, cetyl sulphate, phosphatidic acid or phosphatidyl serine phospholipid charge producing agent, is free of a steroid compound, is free of a fatty acid, and is free of an oil ingredient; and
wherein said lipid microcapsule is capable of delivering one or more transdermal active agents transdermally to the bloodstream.

US Pat. No. 11,065,208

MINERAL COATED MICROPARTICLES FOR CO-DELIVERY OF ANTI-INFLAMMATORY MOLECULES WITH NUCLEIC ACIDS TO IMPROVE GENE DELIVERY OUTCOMES

Wisconsin Alumni Research...


1. A composition comprising:a mineral coated microparticle comprising:
at least one mineral layer;
a ribonucleic acid and at least one of an interferon binding protein and an interferon inhibitor.

US Pat. No. 11,065,468

OPTICAL DEVICE

Essilor International, C...


1. An optical lens configured to be worn by a subject, the optical lens comprising:an optical substrate provided with an optical spectral filter configured to inhibit transmission of at least one of UV or blue light by inhibiting transmission of wavelengths from 380 nm to 455 nm at an inhibition rate within a range of 20% to 100%,
wherein the optical lens that is configured to be worn by the subject is further configured to allow retinal exposure of an eye of the subject through the optical lens to at least one range of wavelengths in visible light spectrum wavelengths of 460 nm to 530 nm, and
wherein the optical filter is configured to selectively transmit light within the at least one range of wavelengths selected with an average light transmittance value greater than or equal to 50%.

US Pat. No. 11,066,503

VERY SOFT, NON-STICKY AND TRANSPARENT STYRENIC THERMOPLASTIC ELASTOMER COMPOSITION

INEOS STYROLUTION GROUP G...


1. A thermoplastic elastomer composition comprising components a), b), and c):a) 90.9 to 69.0 wt.-% of at least one star-shaped block copolymer A of the structure[S1?(S/B)k?(S/B)l?(S/B)m?S2]n?X??(I),


where S1 and S2 are polymer blocks made from at least one vinylaromatic monomer and S/B are random copolymer blocks made from at least one vinylaromatic monomer and at least one diene forming a soft phase; X is a coupling center derived from a polyfunctional coupling agent;b) 9.1 to 31.0 wt.-% of a plasticizer B; and
c) 0 to 2.0 wt.-% of further additives C;
wherein the sum of components a), b), and c) is 100 wt.-%;
the arms S1?(S/B)k?(S/B)m?(S/B)m?S2 are identical;
the proportion of the blocks S1 and S2 (forming a hard phase), based on the entire block copolymer A, is from 24 to 40 wt.-%;
the vinylaromatic monomer/diene (=S/B) ratio of all of the blocks (S/B) is from 1/0.45 to 1/2.5;
the S/B-ratio of the blocks (S/B)k, (S/B)l and (S/B)m is different from each other; the S/B-ratio of the blocks (S/B)k and (S/B)m is lower than the S/B-ratio of the block(s) (S/B)l;
the weight ratio of blocks S2/S1 is from 0.1 to 0.8; and
the weight average molar mass Mw (determined by GPC according to ISO 16014-3:2012) of the block copolymer A is from 220000 to 450000 g/mol;
n is a natural number from 1 to 8;
k and m are 1; and
l is a natural number of at least 1; and
the plasticizer B isb1) a mixture composed of mineral oil B1 and at least one cyclohexane 1,2-dicarboxylic acid C8 to C10 dialkyl ester B2; or
b2) a mixture composed of mineral oil B1 and at least one vegetable oil B3 having an iodine value (g/100 g) of no more than 130.


US Pat. No. 11,064,695

AGRICULTURAL FORMULATIONS, USES THEREOF AND PROCESSES FOR PREPARATION THEREOF

VALENT U.S.A., LLC, Waln...


1. A stable agricultural formulation comprising:about 5.3% w/w ethaboxam:
about 2.8% w/w metalaxyl;
about 3.5% w/w 3-(difluoromethyl)-1-methyl-N-[(3R)-1,1,3-trimethyl-2,3-dihydroinden-4-yl]pyrazole-4-carboxamide;
about 43% w/w propylene glycol;
water;
from about 1.9% to about 2.5% w/w methyloxirane polymer;
about 0.2% w/w of a sodium salt of naphthalene sulfonate condensate;
from about 0.5% w/w to about 0.7% w/w a mixture of sodium salt of alkyl vinyl ether/maleic acid half-ester copolymer and polyvinyl pyrrolidone;
about 0.02% w/w of a silicone emulsion; and
from about 0.12% to about 0.24% w/w of a first component comprising about 19.3% w/w of 1, 2-benzisothiazolin-3-one, wherein w/w of 1,2-benzisothiazolin-3-one denotes weight by total weight of the first component,

wherein w/w denotes weight by total weight of the composition formulation unless otherwise indicated.
US Pat. No. 11,065,209

USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY

GW Research Limited, Cam...


1. A method of treating seizures in a patient suffering from Tuberous Sclerosis Complex (TSC) comprising administering cannabidiol (CBD) to the patient, wherein the CBD has a purity of at least 98% (w/w) CBD, and wherein the CBD is administered at a dose ranging from 5 mg/kg/day to 25 mg/kg/day.
US Pat. No. 11,065,210

REDUCTION OF ADIPOSE TISSUE

10XBIO, LLC, La Jolla, C...


1. A method of reducing subcutaneous adipose tissue in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical formulation comprising polidocanol, wherein the pharmaceutical formulation is administered within a plurality of treatment sessions, wherein each treatment session is spaced by at least 14 days.
US Pat. No. 11,065,211

ISOXYLITONES MEDIATED NEUROGENESIS


1. A method for activating transcription genes NeuroD1 and Neurogenin (Ngn) in cortical, hippocampal and neural progenitor cells to treat patients suffering from cerebral ischemia, Alzheimer's disease, Parkinson's disease, or traumatic brain injury, by exposing said cells to a therapeutically effective amount of isoxylitones ((E/Z)-1-(3,5,5-trimethyl-2-cyclohexen-1-ylidene) propan-2-one), the acid analog (E/Z)-1-(3,5,5-trimethyl-2-cyclohexen-1-ylidene) acetic acid, or a salt thereof.
US Pat. No. 11,065,213

AMANTADINE COMPOSITIONS AND PREPARATIONS THEREOF

Adamas Pharma, LLC, Emer...


1. An oral pharmaceutical composition, comprising:a drug, wherein the drug is amantadine or a pharmaceutically acceptable salt thereof, and wherein said oral pharmaceutical composition comprises from 50 mg to 500 mg of the amantadine or an equivalent amount of the pharmaceutically acceptable salt thereof; and
at least one excipient that modifies the release of at least a portion of said drug;
wherein said oral pharmaceutical composition has a dissolution profile of said drug which shows:(i) 0% to 10% in 2 hours,
(ii) 3% to 14% in 4 hours,
(iii) 23% to 40% in 6 hours, and
(iv) not less than 80% in 12 hours;
wherein the dissolution profile is determined with a USP Type 2 apparatus (paddles) at 50 rpm at 37.0±0.5° C. with 500 ml water as the dissolution medium;

wherein said oral pharmaceutical composition provides (i) a Tmax for amantadine of 11 to 19 hours, and (ii) an AUC0-inf for amantadine of 44 to 72 ng*hr/ml per mg of said drug, and (iii) a pAUC0-8 for amantadine of 1.0 to 2.0 ng*hr/ml per mg of said drug, when said oral pharmaceutical composition is dosed in healthy subjects of a single dose, human pharmacokinetic study, wherein the subjects are dosed in the morning after an overnight fast; and
wherein the oral pharmaceutical composition comprises less than 2000 ppm of organic solvent.

US Pat. No. 11,066,508

POLYESTER-MODIFIED POLYBUTADIENOLS FOR PRODUCING POLYURETHANE ELASTOMERS AND THERMOPLASTIC POLYURETHANES

BASF SE, Ludwigshafen (D...


1. A polyurethane obtainable by reaction of:a) 30 to 150 parts by weight of polyisocyanates A selected from the group consisting of modified 4,4?-methanediphenyl diisocyanate, unmodified 4,4?-methanediphenyl diisocyanate, higher nuclear homologs of 4,4?-methanediphenyl diisocyanate, isocyanate groups containing prepolymers based on 4,4?-methanediphenyl diisocyanate and polyetherols, and mixtures thereof,
b1) 100 parts by weight of block copolymers formed from a polybutadienol and a cyclic ester as component B1,
b2) 4 to 15 parts by weight of at least one of diols as low molecular weight extenders and triols as crosslinkers, each having a molecular weight of 62 to 500 g/mol as component B2,
c) 0 to 100 parts by weight of polymeric compounds C having at least 2 isocyanate-reactive hydrogen atoms, selected from the group consisting of
polyetherols, polycarbonate, polyols and polyesterols having a molecular weight of 500 to 12,000 g/mol and an average functionality of 2 to 6,
d) 0 to 5 parts by weight of catalysts D,
e) 0 to 3 parts by weight of water E,
f) 0 to 10 parts by weight of physical blowing agents F, and
g) 0 to 100 parts by weight of auxiliaries, added-substance materials, and mixtures thereof as component G, selected from the group consisting of surface-active substances, foam stabilizers, cell regulators, release agents, fillers, dyes, pigments, hydrolysis control agents, flame retardants, odor-absorbent substances, fungistatically active substances and bacteriostatically active substances;
wherein the polyisocyanates A are reacted with a mixture of components b1), b2) and optionally one or more of components c), d), e), f), and g),
wherein the polyol component B1 has a number average molecular weight in the range from 600 to 15,000 g/mol, an ?-caprolactone fraction of from 10 to 50 wt. %, and an OH functionality of 1.5 to 2.2, and
wherein the extender of component B2 is 1,4-butanediol.

US Pat. No. 11,064,700

METHODS TO INCREASE CORN GROWTH

VALENT BIOSCIENCES LLC, ...


1. A method of improving corn growth comprising applying an effective amount of gibberellic acid (GA3) and abscisic acid (ABA) to the corn plant, wherein the weight ratio of GA3:ABA is from about 9.3:1 to about 14:1.
US Pat. No. 11,065,214

COMBINATION THERAPIES WITH DISULFIRAM

Spring Discovery, Inc., ...


1. A method for inhibiting and/or reducing pyroptotic cell death in a cell, the method comprising contacting the cell with an active agent that is disulfiram and a potentiating ingredient that is tert-Butylhydroquinone (TBHQ), thereby inhibiting and/or reducing pyroptotic cell death, wherein the amount of disulfiram is from about 5 mg to about 500 mg and the amount of TBHQ is from about 0.02% to about 56% by weight of disulfiram and a combination of disulfiram and TBHQ provides a synergistic effect.
US Pat. No. 11,066,509

CONDUCTIVE PASTE COMPOSITION, DEVICE COMPRISING ELECTRODE FORMED FROM SAME, AND METHOD FOR PRODUCING CONDUCTIVE PASTE COMPOSITION

KANEKA CORPORATION, Osak...


1. A conductive paste composition comprising:1 to 10 parts by weight of a binder (A);
2 to 20 parts by weight of an epoxy monomer (B);
1 to 20 parts by weight of a crosslinking agent (C); and
70 to 95 parts by weight of a conductive filler (D),
wherein the binder (A) is a homo-condensate of a compound represented by a general formula (I), or a condensate of the compound represented by the general formula (I) and a compound represented by a general formula (II), with the condensate including a reactive oligomer having a siloxane bond as a main skeleton and comprising a plurality of oxirane rings as an organic group,
wherein the general formula (I) is defined by R1—(SiR2a(OR3)3-a) wherein R1 is an alkyl group having 1 to 10 carbon atoms, the terminal of which is substituted with an epoxycyclohexyl group, each R2 is independently a hydrogen atom or a monovalent hydrocarbon group selected from an alkyl group having 1 to 10 carbon atoms, an aryl group having 6 to 25 carbon atoms, and an aralkyl group having 7 to 12 carbon atoms, each R3 is independently a hydrogen atom or an alkyl group having 1 to 10 carbon atoms, and a is an integer of 0 to 2;
wherein the general formula (II) is defined by R4—(SiR2a(OR3)3-a), wherein R4 is selected from a substituted or unsubstituted alkyl group having 1 to 10 carbon atoms, an alkenyl group and a substituted aryl group, and does not have an epoxy-structure-containing group, and R2, R3, and a are as defined above;
wherein the epoxy monomer (B) comprises an oxirane ring, and
wherein the total amount of the binder (A), the epoxy monomer (B), the crosslinking agent (C), and the conductive filler (D) is 100 parts by weight.

US Pat. No. 11,065,215

BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS

Anji Pharma (US) LLC, Bo...


1. A method for treating a disorder of glucose metabolism in a patient in need thereof, comprising administering to the patient a pharmaceutical dosage form comprising metformin or a salt thereof, wherein said pharmaceutical dosage form is adapted to have an onset of release of said metformin or a salt thereof distal of the duodenum and to provide at least 20% less relative bioavailability of metformin as measured by plasma area under curve (AUC) resulting from administration of said pharmaceutical dosage form, compared to an immediate release composition having the same amount of said metformin or a salt thereof, and wherein the daily dose of said metformin or a salt thereof is between about 1500 mg and about 2000 mg.
US Pat. No. 11,066,511

OLIGOMERIC POLYOL COMPOSITIONS

Presidium USA, Inc., Dov...


1. An oligomeric polyol composition comprising at least one oligomeric polyol component, at least one monomeric polyol, and at least one polyhydroxylated aromatic compound;wherein the at least one oligomeric polyol component comprises residues of either or both of the at least one monomeric polyol and the at least one polyhydroxylated aromatic compound linked by one or more carbonate groups and optionally one or more oxygen ether groups; and
wherein the at least one monomeric polyol comprises more than three hydroxyl groups and comprises one or more oxygen ether groups.

US Pat. No. 11,064,703

ANTIFUNGAL PAENIBACILLUS STRAINS, FUSARICIDIN-TYPE COMPOUNDS, AND THEIR USE

BASF SE, Ludwigshafen (D...


1. An agrochemical composition comprising:(1) a Paenibacillus strain, which is selected from the group consisting of:a) strain Lu16774 deposited with DSMZ under Accession No. DSM 26969;
b) strain Lu17007 deposited with DSMZ under Accession No. DSM 26970;
c) strain Lu17015 deposited with DSMZ under Accession No. DSM 26971;

andd) a strain which comprises a DNA sequence exhibitingd1) at least 99.6% nucleotide sequence identity to the DNA sequences SEQ ID NO:4 or SEQ ID NO:9; or
d2) at least 99.8% nucleotide sequence identity to the DNA sequence SEQ ID NO:14; or
d3) at least 99.9% nucleotide sequence identity to the DNA sequences SEQ ID NO:5 or SEQ ID NO:10; or
d4) at least 99.2% nucleotide sequence identity to the DNA sequence SEQ ID NO:15; or
d5) at least 99.2% nucleotide sequence identity to the DNA sequences SEQ ID NO:6 or SEQ ID NO:11; or
d6) at least 99.8% nucleotide sequence identity to the DNA sequence SEQ ID NO:16; or
d7) at least 99.8% nucleotide sequence identity to the DNA sequences SEQ ID NO:7 or SEQ ID NO:12; or
d8) at least 99.3% nucleotide sequence identity to the DNA sequence SEQ ID NO:17; or
d9) 100.0% nucleotide sequence identity to the DNA sequences SEQ ID NO:8 or SEQ ID NO:13; or
d10) 100% nucleotide sequence identity to the DNA sequence SEQ ID NO:18; and


(2) at least one auxiliary selected from the group consisting of buffers, surfactants, dispersants, emulsifiers, wetters, adjuvants, solubilizers, penetration enhancers, protective colloids, adhesion agents, thickeners, humectants, repellents, attractants, feeding stimulants, compatibilizers, bactericides, anti-freezing agents, anti-foaming agents, colorants, tackifiers, and binders.

US Pat. No. 11,065,217

USE OF SHORT CHAIN FATTY ACIDS FOR THE TREATMENT AND PREVENTION OF DISEASES AND DISORDERS


1. A method of causing disappearance of a psoriatic lesion in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition, wherein the pharmaceutical composition comprises in a unit dosage form:a) a therapeutically-effective amount of butyric acid or a pharmaceutically-acceptable salt thereof;
b) a therapeutically-effective amount of propionic acid or a pharmaceutically-acceptable salt thereof;
c) a therapeutically-effective amount of an inorganic magnesium salt; and
d) a therapeutically-effective amount of Vitamin D3,

wherein the unit dosage form does not comprise a fatty acid that has at least five carbon atoms, and wherein the disappearance of the psoriatic lesion occurs within about three weeks of administration of the unit dosage form to the subject.
US Pat. No. 11,066,512

METHOD OF PREPARING OLIGOMERIC POLYOL COMPOSITIONS

Presidium USA, Inc., Dov...


1. A method comprising:reacting one or more compositions containing one or more polyhydroxylated aromatic moieties with one or more monomeric polyols containing one or more oxygen ether groups having more than three secondary hydroxyl groups in the presence of at least one activating agent and an effective amount of at least one of a catalyst, a promoter or a mixture thereof, at a temperature sufficient to cause formation of a product oligomeric polyol composition comprising:
(i) at least one oligomeric polyol component;
(ii) the at least one monomeric polyol; and
(iii) at least one free polyhydroxylated aromatic compound;wherein the at least one oligomeric polyol component comprises residues of either or both of the at least one monomeric polyol and the at least one polyhydroxylated aromatic compound linked by one or more carbonate groups and optionally one or more oxygen ether groups.


US Pat. No. 11,064,704

NATURAL PRODUCT FORMULATIONS WITH IMPROVED RESIDUAL INSECT REPELLENT/DETERRENT ACTIVITY

University of Mississippi...


1. A mosquito repellent/deterrent comprising a mosquito repellant/deterrent amount of at least one of carrot seed essential oil or carotol and mixtures thereof further comprising DEET said deterrent being either alone or in an acceptable carrier therefor, wherein, in the case of mosquitoes that are vectors of disease causing pathogenic microbes, the repellent/deterrent is additionally effective for preventing infection with such diseases.
US Pat. No. 11,065,218

COMPOSITIONS AND METHODS FOR TREATING CHRONIC INFLAMMATION AND INFLAMMATORY DISEASES

Infirst Healthcare Limite...


1. A pharmaceutical composition formulated as a suspension for oral administration, the suspension comprising solid particles of a non-steroidal anti-inflammatory drug (NSAID) in an oil carrier, the NSAID solid particles in an amount of at least 20% by weight of the pharmaceutical composition, the oil carrier in an amount of at least 10% by weight of the pharmaceutical composition, and the oil carrier comprising (i) at least 80% of one or more free fatty acids, each of the one or more free fatty acids having at least 8 carbon atoms and being a liquid at room temperature and (ii) phospholipid.
US Pat. No. 11,066,514

SOIL RELEASE POLYMER COMPOSITION COMPRISING AN ANIONIC MODIFIED POLYESTER


1. A method of making an opaque liquid detergent composition comprising the steps of:a. providing a polymer premix, wherein the polymer premix consists of:i. between about 5% and about 40% by weight of the polymer premix of an anionic polyester terephthalate polymer, wherein the anionic polyester terephthalate polymer has a polyester terephthalate backbone grafted with one or more anionic groups;
ii. between about 55% and about 85% by weight of the polymer premix of a solvent, wherein the solvent is a non-aqueous solvent selected from the group consisting of ethanol, propanol, butanol, ethylene glycol, propylene glycol, dipropylene glycol, tripropylene glycol, polyethylene glycol, polypropylene glycol, glycerol, trimethylene glycol, and mixtures thereof; and
iii. between about 5% and about 40%, by weight of the polymer premix, of water;

b. providing a surfactant premix, wherein the surfactant premix comprises between about 10% and about 70%, by weight of the surfactant premix of a non-soap surfactant;
c. combining the polymer premix and the surfactant premix in a weight ratio of the polymer premix to the surfactant premix of between about 2:1 and about 1:25;
d. mixing the polymer premix and the surfactant premix;
e. optionally adding one or more adjunct ingredients;
f. collecting the final opaque liquid detergent composition,

wherein ‘opaque’ means the liquid composition having less than about 1% transmittance measured using a ColorQuest XE spectrophotometer, using 2.5 mL PS cuvettes (1 cm path length), measuring a range from about 400 to about 700 nm when the liquid composition is measured neat.
US Pat. No. 11,065,220

ANTI-PATHOGENIC THERAPEUTIC COMPOSITIONS

Wintermute Biomedical, In...


1. An anti-pathogenic therapeutic composition comprising a mixture of L-Arginine, undecylenic acid and cassic acid, wherein the cassic acid is encapsulated in the undecylenic acid, and wherein the percentage of cassic acid in the mixture is greater than 0.03% w/w of the mixture.
US Pat. No. 11,066,515

POLYESTER RESIN COMPOSITION AND METHOD OF PRODUCING SAME

Toray Industries, Inc., ...


1. A polyester resin composition that satisfies formulas (I) to (IV):an amount of generated linear oligomers (weight ratio with respect to said polyester resin composition)<900 ppm??(I)
?COOH/COOH?2.0??(II)
5 ppm?Mn content (weight ratio with respect to said polyester resin composition)?40 ppm??(III), and
4 ppm?Na content (weight ratio with respect to said polyester resin composition)?40 ppm??(IV)
wherein ?COOH is an increased amount of COOH end groups (equivalent/ton) after a moist-heat treatment under saturated steam at 155° C. for 4 hours, and COOH is an amount of carboxyl end groups (equivalent/ton) in said polyester resin composition before said moist-heat treatment, and
the total content of elements selected from nitrogen, sulfur and a halogen (weight ratio with respect to said polyester resin composition) is less than 10 ppm.

US Pat. No. 11,065,221

BUTHIONINE SULFOXIMINE AND A METALLODRUG FOR THE TREATMENT OF CANCER, HIV OR A RHEUMATIC DISEASE


1. A method of treating malignant immune hyperactivation in a human, wherein the method comprises administering:(a) buthionine sulfoximine (BSO) at a dosage of less than or equal to 9 mg/kg, and
(b) a gold-containing metallodrug at a clinically-acceptable dosage.